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The acute inflammatory response to biological stress involves a highly conserved cascade of 
events mediated by a large array of cells and molecules. While not intrinsically detrimental, 
inflammation can cause secondary or ancillary damage to tissues, which in turn leads to the 
production of molecules that amplify inflammatory response and, in extreme cases, promote 
organ dysfunction and death. Therefore, there is a need to identify and modulate dysregulated 
inflammatory processes while allowing healthy inflammation to carry on. While in vitro and in 
vivo studies have brought many insights into the components and dynamics of the inflammatory 
response, computational techniques are becoming increasingly relevant to tease out complex 
relationships and inter-dependencies that may not be directly measureable. In this dissertation, 
we explore a computational model of pressure ulcer formation that generates tissue-realistic 
output and clinically-relevant predictions. By simulating basic inflammatory mechanisms and 
ischemia/reperfusion injury to soft tissue, our model spontaneously produces both resolving and 
ulcerative inflammatory patterns from a single set of parameter values. We use statistical 
methods to explore which mechanisms in the model are responsible for this spontaneous 
bifurcation. We also use data-driven methods to examine dynamics of inflammatory mediators 
during in vitro murine hepatocellular stress. Our results lead to identification of MCP-1 as a 
clinically-predictive inflammatory mediator in human trauma patients.  
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1.0  INTRODUCTION 
Inflammation has evolved as a response to danger that functions to eliminate threats and restore 
the body to homeostasis. This is accomplished by clearing debris and pathogens before sensing 
tissue damage and initiating repair machinery. As a well-coordinated communication network, 
inflammation is a critical and necessary process that allows organisms to deal with a rapidly 
changing and often hostile environment. While not intrinsically detrimental, inflammation can 
cause secondary or ancillary damage to tissues, which in turn leads to the production of 
molecules that amplify inflammatory response and, in extreme cases, promote organ dysfunction 
and death (92). Many diseases, such as cancer, diabetes, atherosclerosis, Alzheimer’s, and 
obesity are also associated with dysregulated inflammation. This feedback loop of damage to 
inflammation to damage also underlies the basis of multiple organ dysfunction syndrome 
(MODS) following trauma. Unmediated inflammation can cause damage to remote organs that 
were not involved in the initial traumatic injury. This, coupled with the initiating trauma is often 
fatal to patients who would have otherwise survived the initial assault. In wound healing, 
inflammation can be essential to clear out invading pathogens, but overactive pro-inflammatory 
cells can cause additional tissue damage before healing mechanisms are engaged. This additional 
damage can incite new inflammation, engaging the positive feedback mechanism mentioned 
above, leading to chronic wounds. 
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The acute inflammatory response to biological stress (e.g. infection or tissue 
injury/damage) involves a highly conserved cascade of events mediated by a large array of cells 
(e.g. mast cells, macrophages, neutrophils, natural killer cells, dendritic cells, and T- and B-
lymphocytes) and molecules (inflammatory cytokines, free radicals, and Damage-Associated 
Molecular Pattern molecules [DAMPs]) that locate invading pathogens or stressed/damaged 
tissue, alert and recruit other cells and molecules, eliminate the offending agents, and finally 
restore the body to equilibrium. The interplay of these functional modules is what determines the 
success or failure of the inflammatory response. These intracellular signaling networks and their 
products, including diffusible molecular mediators, are in essence the carriers of information in 
the network of inflammatory communication and therefore possible targets for intervention. The 
problem is that any given pathway or mediator may exert either beneficial or detrimental effects 
in a dynamically varying fashion based on the nature of the wound and the particular aspects of 
the individual patient. Selecting likely therapeutic targets for wound healing – in a rational 
fashion that takes into consideration this complex system as a whole – is thus a tremendously 
difficult task.  
Chronic, non-healing wounds present a significant burden of both time and money to the 
healthcare community. Wounds, whether developed in hospital or present on admission, pose a 
great threat to a patient’s health. They provide an opportunity for pathogens to invade and simply 
divert resources that the body could be using to restore health elsewhere. Furthermore, the 
inflammatory response incited can lead to extreme complications, especially when it becomes 
dysregulated. Wounds pose a specific problem to researchers in that they cannot be sampled 
clinically, without necessarily perturbing their course. In addition, it is essentially impossible to 
modulate all possible mechanisms of inflammation and wound healing in an attempt to find 
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novel therapies. While mathematical modeling has been useful in helping to integrate these 
mechanisms, the increasing availability of spatial, non-invasive data (such as clinical 
photographs) and physico-mechanical information suggests the need for new modeling 
approaches to leverage these new data sources to enhance the discovery of effective therapeutic 
regimens. 
An alternative method for studying such a complex, clinically-realistic system is to use a 
mechanistic computational model based on literature knowledge, which could be compared to 
data from lab experiments or clinical subjects, which in turn may have applications in 
diagnosing/predicting the wound healing trajectories of individuals or possibly in the design of 
novel therapeutic modalities for wound healing. Extensive work has gone into computational 
studies of wound healing, spanning many stages of this process, from re-epithelialization and cell 
migration to collagen deposition and scar formation, to angiogenesis (84; 90).  
Agent-Based  modeling is an object-oriented, rule-based, discrete event computational 
modeling technique well suited for integrating and synthesizing cellular and molecular-level 
data, and provides a useful translational tool for examining stochastic and spatial aspects of 
inflammation and wound healing (7). In an Agent-Based Model (ABM), agents representing 
individual cellular or molecular components of a system populate a “virtual world,” in which 
their simulated behaviors are governed by rules extrapolated from known data regarding their 
true biological behaviors (7). Component-level mechanistic detail can be included in the rules 
that govern the behavior of agents. Typically, both the qualitative pattern and predicted 
quantitative time evolution of the agents (variables) can be assessed using agent-based models. 
Because the rules in an ABM define local, instantaneous interactions and since the rules 
governing agent behavior are probabilistic, the overall behavior of the system being simulated 
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will often be different than what was hypothesized from the rules put into the model. The power 
of agent-based modeling is highlighted by the degree that these system-level effects, sometimes 
called “emergent phenomena”, reflect real outcomes observed in traditional biological research 
(36). In this dissertation, an ABM of pressure ulcer formation was created and matched to 
clinical images of pressure ulcers in individuals with spinal cord injury. In chapter 2, we describe 
the process of model development, calibration to clinical images, and comparison to mechanistic 
data from the literature. The model was also used as a platform for in silico clinical trials of 
potential therapies. Two distinct, clinically-relevant phenotypes emerged spontaneously from 
simulations of the model despite starting with the same set of parameter values. In chapter 3, 
statistical methods were employed to explore the cause of the spontaneous divergence, with the 
hope of developing mechanistic hypotheses for which treatment strategies could be devised. 
In addition to modeling the synthesis of understood mechanisms, additional questions 
persist about the nature of the complex interactions that make up the inflammatory response. 
Mathematical and computational (in silico) methods have emerged as adjuncts to in vitro and in 
vivo studies of acute inflammation to tease out the dynamics of key mediators (7). For example, 
we have recently applied both mechanistic and data-driven computational modeling to help 
define the dynamic, multi-dimensional inflammatory response to Trauma/ Hemorrhagic Shock 
(T/HS) in vivo (8-12). In chapter 4, we sought to determine if combined in vitro/in silico studies 
could help elucidate key hepatic inflammatory mediators relevant to human T/HS. We identified 
the chemokine Monocyte Chemoattractant Protein-1 (MCP-1) as a main driver of the response of 
hepatocytes in vitro and as a biomarker for organ damage in clinical settings of T/HS, and, more 
generally, suggests a pathway for combined experimental and computational studies to facilitate 
the discovery of novel clinical biomarkers of inflammation. 
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2.0  A TISSUE-REALISTIC, COMPUTATIONAL MODEL OF PRESSURE ULCER 
FORMATION IN INDIVIDUALS WITH SPINAL CORD INJURY 
This chapter comes from a manuscript by the same name that is currently under review at 
Science Translational Medicine. (Ziraldo, C.; Solovyev, A.; Allegretti, A.; Krishnan, S.; 
Henzel, M.K.; Sowa, G.A.; Brienza, D.; An, G.; Mi, Q.; Vodovotz, Y.; A Computational, Tissue-
Realistic Model of Pressure Ulcer Formation in Individuals with Spinal Cord Injury.) In this 
work, I developed an agent-based model of pressure ulcer formation in soft tissue overlaying a 
bony prominence. I incorporated mechanisms of ischemia/reperfusion and inflammatory-induced 
injury and calibrated the model to clinical photographs of people with spinal cord injury. Model 
behaviors were compared to qualitative data from the literature, and emergent phenomena were 
observed that match clinical realities. Sensitivity analysis was performed to determine which 
mechanisms of injury had the greatest influence on model outcomes, and finally the model was 
used as an in silico platform for testing anti-inflammatory therapies, corticosteroids and anti-
HMGB1 antibodies. Once this manuscript is published, the model code will be available at: 
www.pitt.edu/~cirm/spark. 
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2.1 ABSTRACT 
Spinal cord injury (SCI) predisposes those afflicted to pressure ulcers (PU). PU remain a 
significant problem in cost of patient care and quality of life despite advancements in 
mechanistic understanding and technological interventions. An agent-based model (ABM) of 
ischemia/reperfusion-induced inflammation and PU (the PUABM) was created, calibrated to 
serial images of post-SCI PU, and used to investigate potential treatments in silico. System-level 
features of the PUABM recapitulated visual patterns of ulcer formation in people with SCI. 
Sensitivity Analysis of model parameters suggested that increasing oxygen availability would 
reduce PU. An in silico trial of corticosteroids using the PUABM suggested that early 
application of corticosteroids at a sufficiently high dose could attenuate local inflammation and 
reduce pressure-associated tissue damage, but could not reduce PU incidence. An in silico trial of 
neutralizing antibody targeted at Damage-Associated Molecular Pattern molecules suggested no 
efficacy. Thus, tissue-realistic, clinically calibrated models such as the PUABM may yield novel 
mechanistic insights and suggest a therapy development platform for complex inflammatory 
diseases.  
2.2 INTRODUCTION 
Pressure ulcers (PU) affect 2.5 million US acute care patients per year, costing up to $1 billion 
per year (75). They are a significant source of morbidity in hospitalized patients as well as in 
community-dwelling individuals with impaired mobility. These ulcers are especially common 
(80% at some point in life) in people with spinal cord injury (SCI), a condition associated with 
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decreased functional mobility, acutely increased oxidative activity in leukocytes and chronic 
elevation in systemic inflammatory markers (15; 39; 82). Pressure ulcers are thought to arise 
from pressure-induced ischemia, reperfusion injury, shear forces, and moisture (34). Despite 
increased understanding of the underlying mechanisms and improved clinical vigilance, PU 
remain a prevalent problem in hospitalized patients (14).  
The pathogenesis of PU involves activation of the inflammatory response (43; 71), 
consisting of a highly conserved cascade of events mediated by a set of specialized cells (e.g. 
platelets, mast cells, macrophages, and neutrophils) and molecules (inflammatory cytokines, free 
radicals, and Damage-Associated Molecular Pattern molecules [DAMPs]) that demarcate 
stressed/damaged tissue, and alert and recruit other cells and molecules. This inflammatory 
response can either restore the tissue to equilibrium (healing) or propagate self-maintaining 
inflammation that inhibits wound healing and can lead to PU (90). The complex, dynamic 
interplay of the various functional modules of the intertwined inflammatory and healing cascades 
determines the ultimate success or failure of the healing process. These intracellular signaling 
networks and their products, including diffusible molecular mediators, are possible targets for 
therapeutic intervention. However, the complexity of the process as a whole, and the dependence 
of any given pathway or mediator on timing and context, complicates such therapeutic 
approaches.  
We and others have suggested that computational modeling could underlie the rational 
design of therapies for inflammatory diseases, including aberrant wound healing (6; 90). 
Differential equations are the classical method for computational modeling of biological 
processes, and have been used for decades to explore all phases of wound healing, from 
inflammation (98; 99), to wound closure (12; 28; 29; 53; 69; 100), to tissue remodeling and 
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angiogenesis (23; 61; 70). These computational models have incorporated aspects of mechanical 
stress, population dynamics, and biochemical signaling (84). This compendium of differential 
equation models has resulted in important insights into the wound healing response and has 
advanced our understanding of effective wound healing, as well as suggesting underlying 
pathological mechanisms and testing therapies in silico (61; 99).  
The clinical verification of such computational models has been stymied by the 
difficulties inherent in obtaining tissue-level-- especially spatiotemporal-- data regarding the 
dynamics of inflammation and wound healing. While wound healing is well-studied in animal 
systems (32; 50; 80), only recently have experimental methodologies emerged that may allow for 
the study of the time courses of wound healing in humans (50). A continuing complication is that 
time courses of primary samples from humans with chronic wounds are difficult to collect 
without disturbing the very process being measured.  
Wound images are, in theory, both plentiful and non-invasive-- unlike wound biopsies. 
We and others have generated spatially-realistic, agent-based computational models of 
inflammation and tissue injury/healing based on wound healing and inflammation (1; 7; 76; 87; 
94; 95) literature. We hypothesize that wound images could be used to calibrate and validate 
tissue-realistic, mechanistic simulations of inflammation and healing.  
Agent-Based Models (ABMs) allow for the investigation of both space- and time-
dependent dynamics of complex systems via mechanistic simulations. The modeler provides 
behavioral rules that allow the model to proceed stepwise through discrete space and time. It is 
important to note that while the most of the rules that govern model behavior are deterministic, 
the simulation is stochastic and thereby likely replicates the randomness of biological processes. 
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As a simulation progresses, morphological features evolve that may be indicative of the 
trajectory of the simulation (7).  
We report herein on the creation of an ABM of PU formation (the Pressure Ulcer Agent 
Based Model, or PUABM) that incorporates key inflammation mechanisms. Explicitly included 
was the forward feedback loop of inflammation to damage to inflammation that has served as the 
core motif of our prior simulations of inflammation in both systemic and local contexts (90; 93). 
The PUABM replicates the visual morphology associated with the development and resolution of 
post-SCI PU by simulating the effect of repeated ischemia/reperfusion (representing the turning 
of a person with SCI in bed) on vascularized soft tissue overlaying a bony prominence (the 
clinically recognized “pressure points” at which PU typically develop). We demonstrate the 
possible utility of the PUABM as a platform for in silico clinical trials for PU prevention and 
treatment post-SCI, since the prevalence of PU remains high despite great efforts to implement 
strategies for improved patient care (13; 75). Our study therefore suggests the possibility for a 
novel, in silico-aided platform for discovery, diagnosis, and development of therapeutic targets 
in the settings of complex inflammatory diseases in which pattern-oriented data such as wound 
images are readily available. 
2.3 MATERIALS AND METHODS 
2.3.1 Model Implementation 
The PUABM was built using SPARK, a platform designed for agent-based modeling of 
biological systems, freely available for download at: www.pitt.edu/~cirm/spark (86). SPARK 
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models are written in a logo-like language called SPARK-PL and run on a java platform (85) . 
SPARK models contain agents-- autonomous entities that interact with each other and the 
environment, called Space-- and data layers, corresponding to individual species in the 
environment that can diffuse, etc. The behavior of the model is determined by rules that govern 
how and when agents interact and react. These rules are generally written to be interpreted by 
one agent at a time, and therefore are necessarily restricted in scope (both time and space). A rule 
specifies how much an agent should move, produce, change an internal variable, etc. when it 
encounters a certain amount or type of data layer or agent in its immediate neighborhood. Model 
rules can be probabilistic in nature, allowing the model to evolve in a stochastic manner. 
Therefore, the behaviors and patterns produced by simulating several ticks of the model in 
succession arise as emergent phenomena resulting from the accumulated actions of a population 
of agents over time.  
The components of the PUABM are described in Table 2.1, and the operant biological 
mechanisms and tissue structures are shown graphically in Fig.2.1. In the PUABM, simulation 
time is linked to actual time using the lifespans of cellular agents. A macrophage lifespan ranges 
from 100-150 ticks in our simulation, corresponding to 100-150 hours (4-6 days) of actual clock 
time. Neutrophil lifespans range from 10-20 ticks (hours) in the tissue, but increase when 
neutrophils become activated. Each simulation takes roughly five minutes to compute on an IBM 
Power6™ 575 supercomputing node, which has a 32 processor core with each one running at 4.7 
GHz, making it possible to complete approximately 1000 simulations per day. The model 
contains 68 numerical parameters that are set by the modeler and 11 random variables whose 
values are set throughout the course of a simulation by a random number generator. At any given 
tick, the maximum number of agents computed in the model is on the order of 105.  
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Table 2.1: Summary of Agents, Data Layers, and their interactions encoded in the ABM.  
Substances are all encoded as Data Layers; Cells are all encoded as Agents, each with its own 
type. See Fig. 2.1 for schematic. 
Substances in 
ABM Cell Sources in ABM 
Biological Functions in 
ABM 
DAMPs secreted by damaged Tissue cells 
Chemo-attract and 
Activate Neutrophils 
TNF-α secreted by Activated Neutrophils 
Chemo-attract resting and 
M1 Macrophages, activate 
Macrophages to M1 state 
IL-1β secreted by M1 Macrophages 
Chemo-attract resting and 
M1 Macrophages, activate 
Macrophages to M1 state, 
at high levels activate 
Macrophages to M2 state 
TGF-β1 secreted by M2 Macrophages 
Chemo-attract resting and 
M2 Macrophages, activate 
Macrophages to M2 state 
ROS 
secreted by Tissue Cells on 
Reperfusion, by Neutrophils 
on death 
Injure Tissue Cells 
Oxidase produced inside Tissue Cells during Ischemia 
React with Oxygen to 
produce ROS 
Oxygen released by Blood Vessels 
Necessary for Tissue Cell 
health, react with Oxidase 
to produce ROS 
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Figure 2.1. A schematic illustrates how model components interact to simulate two 
mechanisms of injury: ischemia/reperfusion injury and damage due to inflammation.  
A tissue cell (muscle, fat, or skin) is situated over a bony prominence. When pressure is applied, 
oxygen supply is reduced and the cell becomes ischemic, leading to tissue damage. 
Simultaneously, the enzyme xanthine dehydrogenase is converted into xanthine oxidase. Thus, 
reactive oxygen species (ROS) are produced when pressure is released and oxygen flows back to 
the cell, causing further damage. Tissue damage causes the cell to release DAMPs, which, along 
with local concentrations of pro-inflammatory cytokines activate both neutrophils (N) and 
macrophages (M1, M2) when these mediators are present above a given threshold parameter. For 
example, a sufficiently high local concentration of DAMPs activates neutrophils to secrete TNF-α, 
which can activate macrophages to a pro- inflammatory M1 phenotype. Tissue damage is 
ameliorated by anti-inflammatory mediators [TGF-β1]. 
 
2.3.2 Work Flow 
The PUABM was built using an iterative approach (Fig. 2.2). A simpler model of pressure ulcer 
formation (65) was altered to increase mechanistic detail and create clinically relevant model 
output by making rational improvements based on domain knowledge and data from the 
literature. First, the area of tissue simulated in the field was extended. Whereas in the previous 
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version of the model pressure was applied evenly across the entire field, in this version, it was 
applied maximally (value determined by the parameter, pressure-intensity) to a circular area in 
the center of the field and decreasing radially outward. This allowed representation of pressure 
over a bony prominence and the surrounding tissue, which also experiences pressure, but to a 
lessening degree (26; 55). Next, the PUABM code was altered so that neutrophils and 
macrophages enter the tissue in a resting state and can be activated by one of two circulating 
mediators (TNF-α or TGF-β1), which are released upon incitation of inflammation by damage. 
Then, circulating inflammatory cells were removed to a secondary viewing window and the 
colors indicating to tissue health were adjusted to increase the realism of the model’s visual 
output so that it might be compared clinical images. 
Mechanistic details in the PUABM were augmented by incorporating damage to tissue 
via ischemic injury and its counterpart, reperfusion injury. Damage directly associated with 
pressure was removed and a cost was applied to tissue health receiving inadequate oxygen levels. 
(In the previous version, oxygen had positive effects on tissue health, but lack of oxygen was not 
damaging.) A mechanism based on the conversion of xanthine dehydrogenase to xanthine 
oxidase during ischemia (21; 41) was also implemented. The accumulation of xanthine oxidase 
in ischemic cells represents the potential of a cell to experience reperfusion injury, due to 
formation of ROS when oxygen reperfuses (41). The complexity of the inflammatory response 
was increased by creating two subpopulations of activated macrophages, one with pro-
inflammatory (M1 macrophages) and another with anti-inflammatory (M2 macrophages) 
phenotype (58; 66). A fourth mediator was also added. Representing a canonical late-acting pro-
inflammatory mediator, it is released by pro-inflammatory macrophages and labeled IL-1β. 
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After the mechanisms comprising the PUABM were set, model behaviors were explored 
over wide ranges of parameter values and default values were tweaked into ranges producing 
behavior that qualitatively matched the clinical data. Finally, we further investigated dynamics 
encoded in the model by simulating hypothetical and existing therapies. Corticosteroids were 
incorporated as a data layer that could be introduced to the tissue via blood vessels (as in an IV 
injection), while antibodies to DAMPs were simulated as a topical cream applied to the entire 
field. The dose and timing of administrations of each were varied to assess the viability of these 
treatment options. 
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Figure 2.2. Work Flow.  
The ABM was built iteratively, incorporating domain knowledge and data from the literature, then 
calibrated to clinical data. Initially, pressure directly injured tissue, thereby inciting inflammation. 
Ischemia/reperfusion injury was next added as a cause of injury, and the complexity of the 
inflammatory response was increased. Clinical data were next used to calibrate parameters in the 
model, and the model was subjected to sensitivity analysis and in silico trials.  
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2.3.3 Rules: Homeostasis/ Baseline Architecture  
See pseudocode in Appendix for details of all rules. The architecture of the PUABM is 
abstracted from healthy tissue. The PUABM consists of a layer of tissue cells fed by blood 
vessels throughout the tissue that carry oxygen and inflammatory cells. Instead of explicitly 
representing red blood cells, their presence is implicit as oxygen flows through blood vessels 
unaccompanied. Inflammatory cells arrive to the tissue in their native resting state and are not 
activated unless danger signals are released from damaged tissue. Resting inflammatory cells 
move randomly, but can be chemo-attracted to local mediators.  
The agents in the PUABM represent either cell types or cellular structures: neutrophils, 
macrophages, tissue cells, and blood vessels. Data layers are employed to represent mediators in 
a computationally efficient manner (e.g., diffusible cytokines, free radicals, oxygen, xanthine 
oxidase, and exogenously-administered drugs). Each tick of the model represents 1 h of real 
clock time. On each tick, the agents behave according to rules specific to their type: they produce 
and consume oxygen and mediators, are chemo-attracted to and activated (undergo a state 
change) by mediators; and they die, according to their lifespans. Mediators, represented in data 
layers, can be consumed or produced by individual agents or in reactions with other mediators. 
They undergo diffusion and degradation at each tick. 
Tissue health is determined by local concentrations of oxygen, TNF-α, and TGF-β1. The 
inflammatory mediators have straightforward effects on increasing or decreasing tissue health. 
Oxygen can be both beneficial and detrimental, depending on whether its concentration is above 
or below a threshold.  
To mimic natural patient-to-patient and cell-to-cell variability, some random variables 
were built into the model. These values were chosen from a given distribution as necessary as 
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simulations progressed. Some examples of random variables are size of each blood vessel agent 
(the blood vessels are all sized within a range but not exactly the same), and macrophage state 
change probability (if the concentration of a mediator is high enough and the random variable is 
in the right range then the agent changes state). 
2.3.4 Rules: Pressure On/Off 
The turning of people with SCI in bed was simulated as alternating cycles of pressure on/off. In 
the PUABM, pressure is simulated by constriction of blood vessels, decreasing the amount of 
material that can flow through them. Without oxygen, tissue cell health begins to decline. 
Ischemic tissue cells accumulate xanthine oxidase enzymes, which represent the capacity of the 
cell to produce damaging free radicals upon reintroduction of oxygen.  
When pressure is released and oxygen again perfuses these cells, reactive oxygen species 
(ROS) are formed proportionally to the concentration of xanthine oxidase present in that cell. 
Free radicals cause damage to the immediate cell and those they encounter via diffusion, but they 
do so in a stepwise manner: tissue cells show no sign of damage from radicals until they have 
accumulated a certain threshold of insults. At that time, their health is reduced drastically.  
2.3.5 Rules: Tissue Damage 
Tissue cells that are stressed (have decreasing health) release diffusible danger signals (Damage-
Associated Molecular Patterns [DAMPs]) that stimulate the inflammatory response by triggering 
the secretion of cytokines by inflammatory cells. Three diffusible mediators represent the 
canonical early pro-inflammatory response, the canonical slower pro-inflammatory response, and 
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the canonical anti-inflammatory response, each of which is secreted by activated neutrophils or 
M1 or M2 macrophages. Neutrophils and macrophages are initially in a resting state, and are 
activated by local concentrations of mediators in a threshold-dependent manner. A local 
concentration of DAMPs above a certain value will activate nearby neutrophils to produce early 
pro-inflammatory mediators (abstracted as the pro-inflammatory cytokine TNF-α). At a certain 
threshold of local TNF-α concentration, resting macrophages will be activated to a M1 
phenotype and begin secreting longer-acting pro-inflammatory mediators (abstracted as IL-1β). 
TNF-α also causes damage to nearby tissue cells, thus re-stimulating the pro-inflammatory 
response. Local concentration of IL-1β above a threshold will activate macrophages to a M1 
(pro-inflammatory) phenotype and, above a higher threshold, IL-1β will induce macrophages to a 
M2 (anti-inflammatory/reparative) phenotype. These phenotype changes are reversible, meaning 
a M2 macrophage could be induced to switch to a M1 phenotype if it encountered the right 
conditions, and vice versa. Active M2 macrophages produce anti-inflammatory mediators 
(abstracted as TGF-β1), which above a threshold will cause further activation of M2 
macrophages (Fig. 1b). TGF-β1 also increases health of nearby tissue cells. 
2.3.6 Implementation: Simulated Clinical Trials 
Treatments with corticosteroids or neutralizing anti-DAMP antibodies were simulated as in silico 
clinical trials. These trials consisted of sets of model simulations in which parameters controlling 
drug dose and timing and tissue response were varied, each independently. 
Corticosteroid administration was simulated as an IV injection. Therefore, steroid 
molecules (implemented as a data layer) were introduced to the tissue via blood vessels (and 
were restricted when pressure was applied). The mechanism of steroid action was to kill 
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inflammatory cells, regardless of their state (active/resting). When neutrophils were killed, some 
ROS was released by the dying cell. 
Anti-DAMPs were simulated as a topical cream administration. A uniform layer of this 
molecule was introduced onto the field as a data layer at the tick specified by the parameter 
designating time of onset. The antibodies’ method of action was controlled by a quenching 
reaction, where local concentrations of DAMPs were reduced by an amount proportional to the 
smaller concentration of the two molecules present: antibody or DAMPs. 
2.3.7 Model Calibration 
Parameter values were tweaked until the model gave qualitative behavior that was clinically 
applicable. The first test was to ensure that the “healthy” tissue was stable, i.e. when unperturbed 
the tissue was able to remain healthy. Clinical data was used as the baseline “reality,” and 
consequently the PUABM is calibrated to SCI tissue, which has some unique properties. For 
uniformity of appearance, only visual properties of sacral ulcers within the clinical cohort were 
considered. The default parameters in the PUABM are calibrated to the tissue properties of these 
ulcers specifically, but the model has the capability to take on new tissue properties by altering a 
subset of the parameters. In examining the inflammatory dynamics of the PUABM, some 
adjustments were necessary to compare the numbers of cells. Because the agents in the model are 
not calibrated to specific numbers of cells, absolute population sizes from the PUABM are 
meaningless. Instead, each population of cells was normalized to bring the cell populations all 
into comparable range. For a given cell type at time t, its population count was normalized by 
dividing by the Euclidean norm of the vector containing counts of that cell type for each tick 
throughout that simulation. This procedure allowed us to compare the relative timing of the 
 20 
peaks of each population. Presumably it is not only the number of cells present that determines 
the level of the response, but also how sensitive those cells might be to their environment, and 
vice versa. Therefore instead of calibrating for total number of cells, we focused on achieving 
reasonable qualitative behaviors. 
2.3.8 Sensitivity Analysis 
Because there are more than 50 free parameters in the model, it was impractical to examine the 
sensitivity of key model outputs to all of parameter space at once. Instead, modules of rules in 
the model that impacted tissue health were identified and used to create groups of parameters. 
Parameters within these groups were then prioritized according to the mathematical degree of 
their effect on the system. For example, a parameter that set the value of an exponent produces a 
more dramatic effect than one that sets a scalar multiple. Therefore, the first parameters varied 
were those controlling threshold values. Simulations initially varied over coarse grained and then 
finer grained threshold value ranges (100 simulations per parameter value). Total tissue damage 
by time t served as a quantitative output measure. From this a sensitivity index could be 
calculated for each parameter, taking the ratio of change in damage to change in threshold value. 
A second level of sensitivity analysis was designed to examine the interplay between two 
potentially related parameter values (figs. 2.10-12). This allowed direct comparison of the 
sensitivities of two parameters and also revealed any secondary effects that occurred when the 
two changed in a combinatorial way. Parameters were chosen from the same “damage module” 
in order to get a sense of the relationships between “sub-processes” in each module. Snapshots of 
the tissue layer in the model across several fixed time points served as the output in order to 
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assess overall damage, presence and size of ulcer, and other qualitative features (data shown for 
only one time point per analysis, other time points not shown). 
2.4 RESULTS  
2.4.1 Model Properties: Overall Description of the PUABM 
The PUABM represents vascularized soft tissue (skin, fat, muscle, or a composite thereof) 
overlaying a bony prominence. The tissue remains healthy as long as it is unperturbed and 
oxygen continues to flow to the field. Pressure-- such as that created by shifting a person’s 
weight-- causes damage to the tissue by compressing the tissue and vasculature over the bone, 
restricting the flow of oxygen to the tissue and secondarily by formation of reactive oxygen 
species (ROS) upon reperfusion (when pressure is relieved). Injured tissue incites activation of 
inflammatory cells, which bring mediators to the field, some of which injure the tissue further. 
The molecular and cellular components of the model are enumerated in Table 2.1. The 
PUABM’s mechanistic performance was compared to experiments from the literature, as 
described in Section 2.4.2.  
 
Next, default parameters were set by comparing the visual output of the model to clinical 
images of PU developed during acute care or inpatient rehabilitation. These images were 
acquired following IRB approval from patients recruited to the study by the University of 
Pittsburgh Rehabilitation Engineering Research Center (RERC) on Spinal Cord Injury. 
Sensitivity analysis was performed, and finally the PUABM was used as a platform for in silico 
trials of strategies to prevent and slow the development of pressure ulcers. The process of model 
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development and implementation is shown graphically in Figs. 2.1 and 2.2 and detailed in the 
Materials and Methods. 
2.4.2 Model Verification against tabular data: the PUABM recapitulates 
mechanistic dynamics of PU formation 
The rules governing inflammatory mechanisms in the PUABM are based on dynamics of acute 
inflammation. These dynamics were initially tested in a simulated acute wound without repeated 
pressure cycles. Because the mediators in the simulation represent amalgams of several 
mediators, the dynamics were tabulated at the cellular level. In a successful implementation of 
these mechanisms, tracking activation of neutrophils and macrophages would reveal cellular 
dynamics similar to those found in settings of acute inflammation.  
Two characteristic patterns of inflammatory cell dynamics spontaneously emerged from 
the same set of default parameter values. The timing of peaks was always the same, but that is 
where the similarities end. Every inflammatory cell count in the first pattern was at its maximum 
and still increasing at the end of the simulation (Fig. 2.3). In the second characteristic pattern, 
every cell type except M2 macrophages peaked well before the end of the simulation in the 
second pattern (Fig. 2.4). In fact, neutrophil counts dropped to zero relatively early in the time 
course and did not rise again. Tissue cell counts from simulations corresponding to each of the 
characteristic patterns suggested that every simulation that had the first pattern of inflammatory 
dynamics resulted in an ulcer, while all simulations corresponding to the second pattern did not. 
This was also verified by qualitative spatial pattern matching of visual outputs from simulations 
with both types of inflammatory dynamics. 
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Figure 2.3. Ulcerative Inflammatory Dynamics.  
A 35% initial injury without pressure is sufficient to induce self-perpetuating, damaging 
inflammation, leading to an ulcer. The relative dynamics of the response are as expected from the 
literature: an initial influx and activation of neutrophils, followed by M1 macrophages, and then 
followed by M2 macrophages.  
 
Figure 2.4. Non-progressing Inflammatory Dynamics.  
In 10-20% of simulations with the same parameters and starting conditions, though the 
inflammatory response was incited, it did not become self-sustaining and consequently no ulcer 
formed. The trajectories of inflammatory cells are characteristic of each of these outcomes. Data 
were normalized per cell type, and so quantities are not relative.  
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If tissue damage was indeed caused by both ischemia and reperfusion, then all else being 
equal, a period of ischemia would be expected to cause less tissue damage than the same period 
of ischemia followed by reperfusion. This mechanistic knowledge might be important when 
designing prevention and treatment strategies. This I/R-damage hypothesis was confirmed by 
varying the length of pressure cycles (turning rate) while measuring total tissue damage (Fig. 
2.5). As expected, both ischemia and reperfusion caused tissue damage. Holding the amount of 
ischemic time constant while increasing the number of reperfusion events led to earlier 
ulceration. However, the amount of damage incurred long term with a lower turning frequency 
(and thus longer ischemic periods) reached a level similar to that predicted by simulations of 
higher turning frequency (Fig. 2.5, inset). 
 
Figure 2.5. The ischemia/reperfusion injury mechanism was confirmed by varying the 
period of pressure (on/off) cycles.  
Increasing the length of a pressure cycle allowed us to decrease the number of reperfusion events 
over the same length of ischemia. Pressure switched from on to off (or vice versa) once every 2, 6, 
or 12 hours. y-axis is total damage,  x-axis is time (h). Pressure cycle length did not seem to affect 
the total amount of damage until just after t = 400 h. At that time point, the simulations with the 
shortest cycles (black) show a sudden increase in damage, which visually corresponds to the 
formation of an ulcer (see inset). Eventually, ischemic injury in simulations with the longest cycle 
length (green) causes these simulations to incur more overall damage. Periods of 4, 8, and 10 h 
yield intermediate curves (data not shown).  
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It was important to verify that the damage accumulated throughout a simulation is in fact 
due to the mechanisms of injury encoded in the model, and not to other spurious mechanisms. 
Unperturbed, the tissue remained healthy for thousands of simulated hours (Fig. 2.6 “No 
Pressure” data shown up to 1000 h; this behavior remained unchanged up to 5000 h [data not 
shown]). Some damage was observed when tissue was subjected to 12 h of simulated ischemia 
(Fig. 2.6 “12 hrs constant pressure”), but no further injury to the tissue was observed after release 
of pressure. By comparison, starting with a 35% injury over a patch of tissue at time 0 h (Fig. 2.6 
“35% Initial Injury”) was sufficient to incite the inflammatory response, ultimately leading to PU 
formation. However, this injury was not as damaging as repeated cycles of ischemia and 
reperfusion carried out over the complete time course (Fig. 2.6 “Default Parameters”). 
 
Figure 2.6. Negative controls verify that the model behaves as expected in various situations. 
Green: undisturbed, tissue health is stable for >5000 hours (data past 1000 h not shown). Yellow: 
an initial period of 12 h of ischemia causes damage to the tissue, but after release no further 
damage was incurred. Red: a characteristic damage curve for an ulcer caused by acute 
inflammation after 35% initial injury (similar to 2.3). Blue: a characteristic damage curve for a 
pressure ulcer resulting from the default parameters for the model. 
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2.4.3 Model Verification against spatial data: the PUABM recapitulates visual 
patterns from clinical images  
Tissue health begins to decline in the area directly over the bony prominence within the first few 
hours of pressure cycling in the PUABM. This is manifested by a change in color, from peach to 
red (similar to the erythematous appearance of inflamed tissue). The tissue is able to recover 
some health in the first few rounds of pressure, during periods of reperfusion (data not shown). 
However, after a certain point, the tissue remains red (damaged) despite reflow of oxygen and 
leukocytes to the region. This is comparable to a region of unblanchable skin erythema that is the 
diagnostic criteria for a Stage I PU (31). Tissue health declines further as the simulation 
progresses, increasing the intensity and radius of redness. Tissue cells eventually begin to die, 
leaving behind a white patch to indicate lack of cellular activity at that position. This phenotype 
was considered to be the opening of a PU. From this point onward, the PU grows outward while 
cells near its edge continue to decline in health. 
Simulations of the PUABM were initially compared to reference clinical images of PU 
severity (see Fig. 2.7). The National Pressure Ulcer Advisory Panel (NPUAP) has issued 
guidelines classifying ulcer severity by depth (18), i.e. type of tissue affected. In fact, the 
prevailing notion is that some ulcers begin as deep tissue injury before opening to the epidermal 
surface (17). While the PUABM is two-dimensional, simulations were nonetheless able to 
capture the appearance of a variety of PU of various degrees of severity. Furthermore, detailed 
features such as irregular shapes, jagged edges and secondary ulcers were also recapitulated. 
Specifically, the pattern of damaged tissue surrounding the ulcers was similar in simulations and 
clinical images. Also, as in clinical images, as PU severity increases, the size of the affected area 
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does as well. As shown in Fig. 2.7, simulations could achieve appearances similar to all four 
stages of ulcer progression.  
The simulations also recapitulated evolution of PU development seen in a prospective 
patient cohort. The average time to ulceration post-injury was 20 ± 12 days among the RERC 
subjects, and with default parameters in the model the time to ulceration was 405 ± 6 hours (17 ± 
1 days); there was no statistically significant difference between the simulation predictions and 
the actual RERC ulceration times (p = 0.606 by Mann-Whitney comparison on Ranks). The 
timing of ulceration in the PUABM was a result of model dynamics, since time of ulceration was 
not explicitly encoded to match the clinical data. By choosing parameter values that yielded 
reasonable inflammatory dynamics while obeying constraints for relative lifespans etc., the 
behaviors described here resulted as emerging phenomena. 
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Figure 2.7 Simulations and Clinical Images.  
Simulations achieved visual appearances with characteristics similar to each stage of PU 
development. The first row of clinical images come from the National Pressure Ulcer Advisory 
Panel (npuap.org, used with permission) and are of different subjects. Images in the second row 
are from people with SCI enrolled in a prospective study of PU at each stage. Irregular shapes and 
increasing nearby damage are observed in both sets of clinical data.  
 
The reference clinical images are static snapshots of a dynamic process; moreover, the 
images are from different individuals. Accordingly, individual simulations of the PUABM were 
compared to the dynamics of PU formation in a single individual. Fig. 2.8 shows snapshots from 
a single simulation in which PU reached visual appearances with striking similarities to time 
courses of individual patients. Key characteristics of the PU arise in both simulations and 
patients. Though the simulated bony prominence is circular and the sacral pressure area is 
approximately a triangle, both time courses evolve ulcers with irregular shapes. Furthermore, in 
both simulations and real patients, once an ulcer formed, a second nearby ulcer was more likely 
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to develop. This phenomenon may be due to reduced tissue health and therefore increased 
vulnerability in the immediate vicinity of the ulcer. 
 
 
Figure 2.8. Time courses of simulations versus a clinical time course. 
Numbers indicate days post-injury. Simulated ulcers evolve with visual characteristics that match 
PU progression observed in people with SCI. Two simulation time courses are matched against 
one patient from our study. We match key features: irregular shapes, nearby satellite ulcers, and 
decreasing tissue health across the field. 
 
2.4.4 Parameter Sensitivity Analysis: the most sensitive parameters in the PUABM 
are those related to oxygen and TNF-α   
It is important to understand the range of behaviors that a computational model can achieve, 
under what conditions these behaviors appear, and the likely mechanism by which those 
outcomes are achieved. While the structure of a given computational model can, of course, 
dictate its ultimate behaviors, much of the behavior of a model can be determined by the values 
of its parameters (22; 59; 74; 81; 83). Accordingly, parameter sensitivity analysis was carried out 
in order to gain an understanding of how variations in parameters (including initial conditions, 
rates, thresholds, etc.) relate to variations in output (time-evolving health of tissue). Since global 
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parameter estimation can be a computationally daunting task, especially in the setting of 
stochastic ABMs, the parameter sensitivity analysis herein was focused on defined modules of 
the PUABM (Fig. 2.9). 
 
Figure 2.9: Modules for Sensitivity Analysis.  
We partitioned parameter values according to which damage mechanism they affected.  
 
 
Since in the PUABM injury is initiated by repeated pressure cycles, the sensitivity of the 
model to pressure (Fig. 2.10) was examined first. To do so, the maximum intensity of pressure 
(applied to the center of the tissue) was varied along with the length of the pressure interval (this 
number indicates for how many consecutive ticks pressure is applied, equal to the number of 
ticks during which pressure is removed). At t = 400 h (16 d) of simulated time, very little effect 
of pressure interval length was observed. However, a slightly lower degree of damage was 
discerned in the medium-length pressure interval. Pressure intensity appeared to affect tissue 
health negatively. 
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Figure 2.10  Tissue sensitivity to pressure intensity and period.  
All sensitivity analyses are shown with model snapshots at time t = 400 h (approximately 2.5 
weeks). Pressure intensity varies in each row. Each column represents a value of pressure cycle 
length. As the cycle length increases, the number of reperfusion events decreases for the same 
period of ischemia. Increased pressure leads to more damage, while fewer reperfusion events lead 
to lower damage at t=400 h. Default parameters are marked with asterisks. 
 
 
Pressure affects tissue oxygen in the PUABM. The impact of oxygen on tissue health was 
therefore investigated by varying parameters controlling oxygen production (how much oxygen 
is released from a blood vessel at each time interval) and tissue sensitivity to oxygen (a scalar 
factor determining the degree to which epithelial cell health is impacted by local oxygen 
concentrations) (Fig. 2.11). This analysis suggested that when oxygen production is low (or 
zero), tissue health is severely affected, but in a manner that scales with sensitivity to oxygen. At 
high oxygen production levels, however, sensitivity to oxygen concentration was not apparent. 
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Figure 2.11. Tissue sensitivity to oxygen parameters.  
All sensitivity analyses are shown with model snapshots at time t = 400 h (approximately 2.5 
weeks). The parameter governing oxygen production varies in each row. Each column represents a 
value of the parameter controlling how sensitive the tissue is to local oxygen concentrations. 
When oxygen production is plentiful, the simulated tissue becomes insensitive to other oxygen 
parameters (bottom row). Default parameters are marked with asterisks. 
 
 
In a two-way sensitivity analysis, tissue sensitivities to two inflammatory mediators were 
compared to each other (Fig. 2.12), namely the parameter controlling the model’s sensitivity to 
TGF-β1 (the canonical anti-inflammatory mediator) and the parameter controlling sensitivity to 
TNF-α (the canonical early-acting pro-inflammatory mediator). Although all simulation 
snapshots are taken at the same time point, with higher sensitivity to TNF- α, PU appear by t = 
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400 h (16 d); this does not occur at lower sensitivity to TNF-α. The effect of TGF-β1 is less 
pronounced, though there is overall less damage as the sensitivity to TGF-β1 increases. 
 
 
Figure 2.12. Tissue sensitivity to inflammatory mediators.  
All sensitivity analyses are shown with model snapshots at time t = 400 h (approximately 2.5 
weeks). Each column represents a value of the parameter controlling how sensitive the tissue is to 
local TNF-α concentrations. The parameter controlling tissue sensitivity to TGF-β1 varies in each 
row. Increasing sensitivity to TNF-α leads to earlier ulceration and more damage, while increased 
sensitivity to TGF-β1 leads to decreased tissue damage. Default parameters are marked with 
asterisks. 
 
 
The inflammatory response, like most biological processes, is regulated in part through 
signaling mechanisms that, in essence, define thresholds of activation (67). Accordingly, various 
thresholds in the PUABM control state changes of inflammatory cells (e.g., when local TNF-α 
concentration is above threshold, macrophages convert to M1 phenotype.) There is a different 
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threshold for each state change, as illustrated in Table 2.1 and Fig. 2.2. Sensitivity analysis 
suggested that the most sensitive threshold was the concentration of DAMPs necessary to 
activate neutrophils (Fig. 2.13). Most thresholds had a small range over which the output was 
sensitive to the threshold value, and outside of this range the dynamics were stable. This was not 
true for thresholds controlling activation of M2 macrophages. For activation by both IL-1β and 
TGF- β1, as the threshold value increased, so did predicted damage (as expected). However, 
from the number of simulations we performed (100 per parameter value), there seemed to be a 
nonlinear relationship between the thresholds of M2 activation and total damage acquired. There 
were regions in which the output stabilized over a range of parameter values and then at the next 
higher parameter value, the total damage suddenly rose (Fig. 2.13). This phenomenon could be 
an artifact of under-sampling, but if not, it suggests a more complex relationship between the 
number of M2 macrophages and overall damage in the model. 
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Figure 2.13. Sensitivity Analysis of Inflammatory Activation Thresholds.  
(A-E) At every value of each parameter, plotted are data from 100 simulations, each run for 4000 
ticks. Values of total damage at four time points in each simulation were normalized by dividing 
by the maximal possible damage value. Then the mean and SEM was calculated for each 
parameter value at all four time points. This is plotted in the upper graph of each panel. Sensitivity 
coefficients were calculated according to the formula given in panel (F). The Sensitivity 
Coefficient is defined to be the average change in total damage between consecutive values of the 
varying parameter, divided by the amount by which the parameter changed. 
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2.4.5 In silico Clinical Trials: Reducing inflammation reduces overall Damage, but 
does not prevent ulceration in the PUABM 
In silico (simulated) clinical trials are an emerging means of gleaning translational knowledge 
from computational models (4; 27; 48; 64). Accordingly, this methodology was utilized to test 
both current and hypothetical or emerging therapies for inflammation in the setting of post-SCI 
PU. The feasibility of corticosteroids as a treatment was examined for this indication, varying 
dose and timing of corticosteroids to investigate whether reducing inflammation could delay 
ulceration and/or lead to less tissue damage (Fig. 2.14). Corticosteroid administration was 
simulated as suppressing all inflammatory mechanisms. This was implemented by the following 
rule: any activated macrophages or neutrophils die upon encountering at least a threshold amount 
of steroid in their local vicinity of steroid. Corticosteroids led to a reduction of the total damage 
incurred in a simulation when administered early enough and at high enough doses. However, 
with pressure cycling PU still formed, suggesting that the lack of inflammation was insufficient 
to ameliorate the damaging effects of ischemia and reperfusion (Fig. 2.14A).  
By comparison, simulations with an initial acute injury but without pressure responded 
more favorably to steroid intervention (Fig. 2.14B). From qualitative spatial pattern matching, it 
appeared that any dose of steroid greater than zero was sufficient to achieve the full effect in 
both cases. There was, however, more damage incurred when the steroid was applied at later 
times. While overall damage was still less than simulations without steroids, there was 
noticeably more damage in simulations with later onset of steroids, no matter the method of 
injury. 
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Figure 2.14: in silico Corticosteroid Trials.  
Simulations are shown at t = 700 h. We varied both the dose and timing of corticosteroid 
administration, simulated as an injection into the bloodstream, under (A) alternating pressure and 
(B) 40% initial injury conditions. When inflammatory cells were neutralized early enough but 
pressure continued, overall damage decreased, but ulceration was not prevented. Without 
continuous pressure cycles, the earliest dose of steroids was successful in stemming ulcer 
formation, but later applications did not.  
 
 
DAMPs such as HMGB1 have become leading therapeutic targets for inflammatory 
indications (11; 105). Accordingly, dose and timing of anti-DAMPs administration were varied 
over wide ranges using the PUABM; however, no apparent effect was observed (Fig. 2.15A). 
This lack of predicted efficacy may be due to a secondary mechanism of neutrophil activation 
encoded in the model wherein damaged tissue cells can activate neutrophils directly, 
compensating for the lack of DAMPs. Again, the same treatment was simulated on an initial 
acute injury without pressure cycles (Fig. 2.15B), yielding similar results. 
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Figure 2.15: in silico Anti-HMGB1 Trials. 
We then varied both the dose and timing of administration of a neutralizing antibody to HMGB1, 
simulated as a topical cream applied to the entire field. This targeted approach had (A) no apparent 
effect during simulations with alternating pressure, but (B) was able to slow ulcer formation after a 
40% initial injury without pressure. 
 
2.5 DISCUSSION  
The “translational dilemma” centers, in large part, on the inability of traditional, reductionist 
approaches to yield drug targets for the complex diseases that affect today’s patients (5; 10). 
Systems biology (“-omics”) approaches may help identify global system properties and suggest 
dysfunctional biological pathways that may be serve as therapeutic or diagnostic targets. 
However, these approaches are limited in the setting such as wound healing. A key limitation is 
related to the need to obtain material from the affected tissue, and thereby possibly compromise 
the underlying biological process and impair wound healing. A further limitation is due to the 
purely associative nature of the bioinformatics tools used to analyze “-omics” data, which limit 
the ability to extrapolate beyond the conditions used to obtain the data, and also cannot be used 
to predict the effects of perturbations/therapies (8; 90). Mechanistic computational modeling 
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offers the possibility of overcoming this limitation, but traditional, equation-based mechanistic 
models are typically difficult to implement with the kind of spatial realism that could facilitate 
non-invasive comparison to easily obtained image data. Thus, the ability of ABMs to represent 
spatial relationships and tissue patterning effects makes this class of models an appealing 
approach for modeling the biology of wound healing in the context of post-SCI PU. As with 
other applications of biomedical agent-based modeling, simulations generated by an ABM 
concerning wound formation and evolution are marked by global, system-level morphological 
outputs, i.e. spatial patterns with identifiable temporal trajectories. Tracking these morphological 
features – along with numerical data concerning both the temporal trajectories of individual 
components (mediators and cell populations) and “experimental/epidemiologic” output derived 
from performing a series of simulation runs – provide a rich space of output features to which 
hypotheses can be examined, evaluated, and falsified. This process can lead to the generation of 
novel, clinically-relevant hypotheses that can then be further examined in an iterative 
investigatory loop (5; 7). 
Herein, we report for the first time on a tissue-realistic ABM of inflammation and wound 
healing that leads to visual patterns, in a manner that is highly consistent with data obtained from 
PU in people with SCI. We suggest that this approach of using extensive simulations calibrated 
against highly-focused clinical data holds the potential to streamline subsequent in vitro, in vivo, 
and clinical studies (9). 
Tissue-realistic simulations incorporating mechanistic information present multiple 
possibilities at the bedside. The visual output of models such as this one, along with the capacity 
to use the models for in silico clinical studies as we show here, lends itself naturally to both 
diagnostic and drug development applications in which the outcome is often a visual pattern 
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(wounds and other skin lesions [e.g. psoriasis, melanoma], histological and immunohistological 
biopsies, and other medical imaging modalities [e.g. MRI, CAT scan]). After augmentation and 
appropriate additional verification (see below), the model may eventually be used to identify 
individual wound healing phenotypes and trajectories, determine appropriate treatment course, 
and design and test new treatment regimens.  
The design and execution of clinical trials involving multiple concurrent interventions all 
being evaluated at differing dose and dosing levels, is extremely challenging at best, and 
logistically unfeasible in most cases. For complex inflammatory diseases, in silico clinical trials 
could help guide and streamline the selection of therapies and their implementation in 
randomized clinical trials (91; 93). Herein, clinical trials of an established anti-inflammatory 
agent (corticosteroids) as well as a novel therapy currently in clinical trials (neutralizing anti-
HMGB1 antibodies) were carried out in silico. Though leukocyte inhibition has been shown to 
reduce I/R injury and PU formation in rats (71), these in silico studies suggest only a limited 
efficacy for corticosteroids, in line with prior studies (31; 56). Neutralizing anti-DAMP 
antibodies have also been suggested as potential therapies for acute inflammatory diseases, 
though not for wound healing disorders. In the setting of post-SCI PU, our studies suggest that 
anti-DAMP antibodies are unlikely to be efficacious for this indication, as may be anticipated 
from the known role of DAMPs such HMGB1 in promoting wound healing (73; 88; 104). Our 
preliminary results based on sensitivity analysis do, however, point to wound oxygenation as a 
potentially efficacious therapeutic approach for post-SCI PU. Hyperbaric oxygen therapy has 
been shown to be beneficial in healing many types of chronic wounds (47). Paradoxically, 
however, in studies with PU, hyperbaric therapy has not shown significant effects (47). It may be 
that the damage incurred in the settings PU also affects vasculature to the point that they are 
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unable to take up oxygen from the environment. In this case, alternate strategies to deliver 
oxygen to the wound—perhaps a more directed, local application rather than hyperbaric oxygen 
to be delivered via the overall circulatory system-- could be considered. 
There are various limitations to this study. An inherent limitation to modeling is the 
resolution of detail included in the model. The mechanistic information used to inform the rules 
of the PUABM was relatively high-level. For example, we used single mediators to represent the 
actions of entire pathways. These choices were made because the nature of ABMs is such that 
each mechanism could be computed in any given cell at any given tick. It is the sum of these 
parsimonious mechanisms as they are simulated across space and time that gives rise to the 
behaviors of the model. Including too much detail causes simulations to run slowly and on the 
whole may not add much insight on the whole-tissue level. Furthermore, the more details, the 
more difficult the calibration process is. It is a delicate balancing act for the modeler to include 
enough mechanism for the model to be relevant without including too much noise. A related 
limitation concerns the fact that the PUABM is a two-dimensional abstraction of a three-
dimensional layer of tissue above a bony prominence (17; 19) (i.e. simplifying the complex 
environment thought to lead to PU formation). Studies have shown that various tissue layers 
(skin, muscle, bone) have differing susceptibility to nutrient deprivation and other adverse effect 
of pressure loading (e.g., muscle is more susceptible than skin) (17; 19). However, the tissue 
simulated in this model represents an abstracted, composite tissue which responds in a way that 
is more general than any individual layer, but still produces the same dynamics observed 
clinically. Recent work has also suggested an important contribution of strain and tissue 
deformation in the development of pressure ulcers and deep tissue injuries (20; 51). The two-
dimensional nature of the PUABM prevents full exploration of these phenomena, though they 
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are necessarily linked to ischemia/reperfusion events. Nonetheless, the simulated tissue was able 
to achieve a range of appearances matching the appearance of ulcers at various severities in 
clinical photographs (Fig. 2.7). 
Another limitation concerns the availability and frequency of clinical data, especially in 
the earliest stages of ulceration. Given the fleeting nature of tissue edema/redness, it was very 
difficult to obtain images of ulcers in Stage I. Therefore, we cannot be as confident regarding the 
validity of the dynamics of our model in the early phases of each simulation. Complicating 
matters further is the fact that the people with SCI in our study received care for their wounds, 
including debridement of necrotic tissue and thus removal of inflammatory stimuli, as well as the 
presence of other injuries sustained or complications of traumatic SCI. In parameterizing the 
PUABM, we utilized population averages regarding time to formation of PU, and some of our 
parameters may reflect these treatments. This may also explain why other studies tend to find a 
shorter average time to ulceration (3; 40). Another contributing factor is that we defined 
“ulceration” as the moment when the first tissue cell dies, signifying opening of the PU. In 
reality, this could represent a partial thickness Stage II ulceration, but may be more consistent 
with a full thickness Stage III PU with loss of dermal cells. Thus, either a Stage I PU or even a 
deep tissue injury could have already been present. Indeed, the time required to develop a Stage I 
ulcer is quite short (12 ± 5 h) in our simulations, and thus may, in actuality, match reported time 
scales. In the model, any small amount of damage – whether or not this damage is sufficient to 
incite inflammation – does not heal. In the clinical setting, this small amount of damage may not 
be severe enough to stimulate intervention, and as a result may progress or fail to heal.  
The PUABM could be augmented to increase its realism and translational utility by 
simulating standard interventions such as debridement (as we have done in our diabetic foot 
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ulcer ABM) (64), as well as routine complications such as bacterial colonization or infections. In 
addition, the emergent/stochastic phenomenon yielding the possibility of worsening or non-
worsening inflammation subsequent to a single injury from one set of parameter values is 
promising for several reasons. First, this variance mimics the variability observed clinically, 
wherein two patients may present with similar disease states, receive the same treatment, but 
have quite different ultimate outcomes. The PUABM allows us to query the cause of this 
bifurcation, which may yield further diagnostic or therapeutic utility.  
In conclusion, our studies demonstrate the potential utility of tissue-realistic ABMs as a 
platform for mechanistic inquiry and translational application. Given the dire need for new 
therapeutic avenues for complex diseases, we suggest that a platform combining in silico 
approaches with clinical samples, especially images that can be obtained readily and 
inexpensively, may yield novel diagnostic and therapeutic modalities. 
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3.0  ANALYSIS OF AN AGENT-BASED MODEL TOWARD CLINICALLY–RELEVANT 
INSIGHTS 
3.1 ABSTRACT 
As a wound progresses, it develops morphological features that may be indicative of the wound’s 
trajectory. In an ABM, wound formation and evolution is marked by morphological outputs of 
the model. These morphological features -- along with numerical data also generated during 
simulations -- provide a rich space of output features to which hypotheses can be linked. In this 
chapter, we explore methods to take advantage of model outputs to learn how and when 
outcomes are determined. From this information, new treatment strategies can be designed. 
3.2 INTRODUCTION 
To design treatment strategies for pressure ulcers, we sought a more specific understanding of 
pressure ulcer formation aided by the pressure ulcer ABM described in Chapter 2. We have 
shown that in total, the two mechanisms we encoded in the model (I/R injury and acute 
inflammation) are each capable of inducing significant tissue damage. From a clinical standpoint, 
however, a good treatment strategy targets one specific piece of a given mechanism. To identify 
which individual parts of the model have the most influence over its outcome, we examined the 
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effects of individual model parameters including initial conditions, rates, thresholds, etc. We next 
wanted to relate the model parameters to outcomes in an analytical way, so that we have a 
quantitative basis for comparing the effects of each parameter. Understanding the space of 
parameters that leads to one outcome or another also gives information about the mechanism by 
which those outcomes were achieved. Similarly, the parameters that can account for the greatest 
portion of variance in model outputs either are linked to the dominant mechanism of action in the 
model or are encoded in a way that places undue emphasis on that mechanism. It is important to 
understand the range of behaviors that a computational model can achieve and under what 
conditions they appear. It is important to identify these parameters and then make the 
determination as to whether or not the rules are 'fair.' If so, then we can have more confidence 
that the outcomes are realistic. Because all models are abstractions of reality, formal model 
analysis is essential to measure confidence in model predictions. We would like to understand 
how variations in parameters (including initial conditions, rates, thresholds, etc.) relate to 
variations in outputs (time-evolving health of tissue). Therefore, we would like to develop a 
quantitative mapping from model inputs to model outputs, estimating the range of output values 
given the range of input values.  
Stochastic models bring with them an extra layer of uncertainty (given the same set of 
parameters, we may have a distribution of outputs due to stochasticity in the model). This is 
termed aleatory uncertainty, while the variation caused by varying inputs is epistemic 
uncertainty. To characterize this relationship, it is necessary first to separate aleatory from 
epistemic uncertainty. Then, we can characterize each of these phenomena separately, 
proceeding with the epistemic uncertainty as we would with a deterministic model. As we have 
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already explored epistemic uncertainty in the previous chapter, this chapter will focus on aleatory 
uncertainty. 
The fact that we see not only a range of outcomes but two distinct phenotypes arising 
from a singles set of parameter values suggests that the aleatory uncertainty not only  introduces 
noise, but also causes meaningful transitions between health states. We will harness this 
stochastic bimodal variation as powerful information content to understand the dynamics of the 
system and design effective treatments. This variation mimics variation in a population of 
patients who may present with the same intensity of disease, receive the same treatment, but 
experience very different disease progressions. We have found that the two types of outcomes 
we observe in silico strongly correlate with characteristic simulated trajectories of inflammatory 
cells. In figures 2.3-4, notice that the simulation with a resolved inflammatory response has 
almost no active neutrophils in the second half of the simulation. By contrast, in the simulation 
with maladaptive inflammation, after being initially activated all of the inflammatory cells 
remain engaged throughout the remaining time course. This observation could be key to 
understanding the divergence between resolving and maladaptive inflammation in our 
simulations. Indeed, there is evidence of existence of “tipping points” in other settings of acute 
inflammation, where a system crosses some threshold and becomes committed to one outcome or 
another, even before physiological symptoms would predict such inevitability (8; 30; 68). 
According to the inflammatory cell trajectories mentioned above, it would seem that the model is 
already committed to its severity of outcome well before an ulcer forms.  
To examine how this might arise stochastically in the model, we collected inflammatory 
trajectories and other data from simulations, and used this as a feature set to train a classifier for 
tissue health outcomes. We wanted to use sequences of state variable values to predict which 
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outcome a simulation would reach. Next we wanted to know how early in a simulation that 
prediction could be made without loss of accuracy. With this determined we tested our classifier 
by determining at what point the decision had really been made. Saving all internal model 
variables allowed re-simulation under precisely the same conditions from any arbitrary point in a 
time course. By starting at various points along the way, we could see how early every single re-
simulation reached the same outcome class as the original simulation. This greatly narrows the 
time window in which the divergence decision is made, limiting the number of features 
necessary to consider when determining a predictor. This is helpful because the predictor is 
likely more nuanced than the total concentration of one or two state variables; more detailed 
spatial and/or temporal features may play a role. 
At the end of this chapter, we also begin the exploration of global sensitivity analysis by 
examining the qualitative effects of three injury mechanisms: ischemia, reperfusion, and acute 
inflammation. We develop some surprising insights about how each mechanism affects 
qualitative outcomes. 
3.3 RESULTS 
3.3.1 Quantitative Characterization of Bimodal Behavior 
In Chapter 2, we observed that simulations could reach two distinct endpoints, even when 
initiated with the exact same parameter values. This behavior, we reasoned, must arise due to 
stochasticity within the model. The behavior was most prominent in simulations of the acute 
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inflammatory response in the absence of pressure, but was also noticeable when pressure cycles 
were applied (Fig. 3.1). 
 
Figure 3.1. Snapshots at t=1000 showing two distinct outcomes for each set of parameter 
values. 
Eight independent simulations are represented here. Snapshots are arranged with lower damage 
simulations in the top row, for visual impact. All 4 snapshots on the left arose from the same set of 
parameters involving 30% initial injury to the center of the tissue and no pressure cycles. 
Similarly, all four simulations on the right arose from the same set of default parameter values, 
including pressure cycles and no initial injury. 
 
3.3.1.1 Acute Inflammation Incited by Initial Injuries of Varying Degree 
In simulations of acute inflammatory dynamics, the intensity of initial injury was correlated to 
the frequency of ulcerative inflammation (as opposed to resolving inflammation). With a 40% 
initial injury, ulceration was virtually guaranteed whereas a 25% injury only led to ulceration in 
approximately 10% of simulations (Fig 3.2). In order to study the dynamics controlling this 
switch, we focused on simulations with a 30% initial injury, which yielded ulcerative 
inflammatory dynamics in almost 50% of simulations. 
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Figure 3.2. Ulceration rate for various amounts of initial injury, without pressure. 
 
3.3.1.2 Acute Inflammation Incited by a 30% Initial Injury 
Ulceration was defined as having at least one dead tissue cell. Therefore, counting live tissue 
cells gave an indication of whether a simulation had reached ulceration or not. With these 
simulations where the two endpoints are so drastically different, tissue damage levels were also 
indicative of ulceration status. 
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Figure 3.3. Histograms of number of live tissue cells and total tissue damage at t=1000. 
 
 
The distribution of simulations reaching each endpoint was approximated using the 
damage distribution as the input to the Matlab® function, gmmfit. This step is unnecessary with 
two peaks that are so cleanly separated, but becomes necessary with default parameters, where 
the endpoints are not so far from each other. Using the Expectation-Maximization (E-M) 
algorithm, a mixture of two gaussians was approximated using 500 measurements of tissue 
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damage at t=1000. For visual comparison, the probability density function (PDF) estimated by 
kernel smoothing (using uniform bandwidth) was overlaid on the Gaussian Mixture Model 
(GMM) result. 
 
 
Figure 3.4. Approximation of PDF of Damage using Gaussian Mixture Models and Kernel 
Smoothing Estimation. 
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3.3.1.3 Bimodal Behavior in Simulations with Pressure Cycles and Default Parameter 
Values 
Qualitative visual comparison suggested that the multiple-endpoint phenomenon was also 
present in simulations where pressure was applied. The endpoints were not as discrete as above, 
due to addition damage caused by ischemia/reperfusion injury. Therefore, ulceration was no 
longer a defining outcome, as all simulations under these parameters led to an ulcer. What 
appeared to be different, however, was the amount of damage to the tissue surrounding the ulcer. 
Reducing this damage would be a desirable clinical outcome because it may protect a patient 
against further spread of that ulcer and/or lower the risk of developing secondary ulcers in 
nearby tissue. Histograms of live tissue and total damage at t=1000 illustrate the complexity of 
this problem (Fig 3.5). 
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Figure 3.5. Histograms of Live Tissue Cells and Total Damage at t=1000 with default 
parameters (including pressure cycles). 
 
 
We first needed to determine the best estimate for how many separate endpoints are 
represented in the histograms above. We again used E-M to fit GMMs to the data. This time, 
however, we allowed the number of Gaussian distributions in the mixture model to vary from 1 
to 4. We selected the model that was a mixture of two independent Gaussian distributions 
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because it yielded the lowest scores for both Aikikae Information Criteria (AIC) and Bayesian 
Information Criteria (BIC), shown in Table 3.1.  
 
Table 3.1. Information Criteria for fitting a mixture of 1-4 Gaussians to the Total Damage 
data for Default Parameters. 
 
Number of Independent Gaussians 
 1 2 3 4 
AIC 11959.9 11723.8 11728.9 11735.1 
BIC 11969.7 11748.4 11768.2 11789.1 
 
 
Plotted below are the peaks estimated by the mixture of 2 Gaussians model, and on the 
right the kernel-smoothed estimate is overlaid for visual comparison (Fig 3.6). Notably, the 
mixing proportions of these two distributions are different than for the acute inflammation 
simulations. The smaller damage outcomes occur in only approximately 10% of the simulations.  
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Figure 3.6. Approximate pdfs of Damage, as estimated by GMM and Kernel Smoothing. 
 
3.3.2 Source of Bimodal Behavior 
3.3.2.1 Problem and Approach 
Now that we verified that the bimodal behavior is quantifiable, we would like to determine 
which variables in the model are most predictive of outcome. Our first approach was to take 
advantage of the time-dependence of our data by framing the problem as a sequence 
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classification problem. Following the work of Xing et al., (101; 102) we employ a 1-nearest 
neighbor approach. We measure the distance between two sequences by summing the Euclidean 
distances between corresponding time points on the two sequences. A new unlabeled test 
sequence is assigned the same class label as the training sequence that is closest in distance to it. 
With sequences the length of a full simulation (1000 ticks), a relatively good prediction accuracy 
can be expected. The goal of the work of Xing et al. was to determine the “minimum prediction 
length” or the time point before which accuracy begins to decrease. We also look for this time 
point, and use it as an indication of the time by which the simulation is committed to one 
outcome or another. One last modification was to consider shorter prefixes. Because the 
simulations are not committed from the very beginning, the early parts of a time course might 
add unhelpful noise. We compare performance of the 1NN classifier using full length prefixes to 
the same using prefixes less than or equal to 50 ticks in length. 
3.3.2.2 Feature Selection 
The data on which we hope to base a classification was collected during simulations of acute 
inflammation, without pressure. At each tick, recordings were made of total amounts of each 
mediator, oxygen, and tissue damage, counts of each type of activated cell, etc. We also recorded 
spatial information for these variables—a lower resolution grid with local concentrations of each 
of the total measurements mentioned above. Figure 3.7 shows time courses of the total variables, 
color coded for simulation outcome. These time courses revealed distinct patterns for simulations 
leading to either endpoint. 
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Figure 3.7. ABM state variables in resolving and ulcerating simulations (full timecourse). 
Features plotted for simulations starting from 30% initial injury that resolved or resulted in an 
ulcer. 
 
 
Before endeavoring to extract features from time courses of spatial patterns, it seemed 
prudent to see how well the classifier could perform using the lower dimensional time courses of 
total counts. These are the time courses plotted above and below. We notice that a few features 
have patterns that differentiate between ulcerated and resolved simulations early in the time 
course. Re-plotting the features for only the first 200 ticks, it becomes more apparent that some 
features will be more informative than others, especially in making predictions as early as 
possible. The features: total-oxygen, blood-flow, total-antiox, total-radical, and total-oxidase do 
not appear to differentiate between endpoints at all, while activated-neutrophils, total-tnf, and 
total-danger seem promising, especially between 100 and 200 ticks. 
 
 58 
 
 
Figure 3.8. ABM state variables in resolving and ulcerating simulations (t = 0-22). 
Features plotted for only first 200 ticks. Upper panel A plots ulcerated simulations in front of 
resolved; lower panel B plots resolved simulations in front of ulcerated. 
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3.3.2.3 Nearest Neighbor 
To take advantage of the time dependence of the features, a nearest neighbor classification 
scheme was adopted. The training set consisted of data from 100 simulations, labeled according 
to which endpoint was reached. For each simulation in the test set, a pairwise distance was 
computed between itself and each simulation in the training set. The simulation in the training set 
with the shortest distance to a test simulation was called its “nearest neighbor” and the label was 
shared between the two. This method obviously relies heavily on the choice of distance metric, 
here Euclidean distance. The length of the vectors (number of time steps included) is called the 
prefix. When using this method to make predictions, the goal is to get the best possible 
classification with the shortest prefix. For univariate time series, we simply calculated the 
Euclidean distance between each pair of vectors consisting of measurements of a single feature 
through time. For multivariate time series, we calculated the Euclidean distance between two 
feature vectors at each time step and took the Euclidean norm of those distances to be the 
distance between the two simulations. To equalize the contributions of all features, their values 
were normalized to fall into similar ranges before calculating distance.  
The following graphs show the classification error rate of the 1-Nearest Neighbor (1NN) 
Classifier trained on various subsets of the features for the first 200 ticks (fig 3.9). The first step 
was to assess the predictive power of each feature individually. While classification error ranged, 
it never stabilized, and no single feature achieved an acceptably low error rate. This figure also 
makes plain which features are not informative at all. 
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Figure 3.9. Classification Error of 1NN Using Univariate Time Series.  
For each feature, there are two plots. In the foremost (red) the prefix was limited to 50 ticks, at most. For 
these cases, we included ticks [t-49, t]. In the blue, the prefix was left as long as the tick. 
 
 
We next repeated the classification, incorporating information from multiple features into 
each time series (a multivariate time series). We assessed the performance of 1NN using a) all 13 
features, b) 8 features that were not inert across the first 200 ticks (all but total-oxygen, blood 
flow, total-antiox, total-radical, total-oxidase), and c) 3 features that appeared to differ the most 
among the two outcomes before 200 ticks (activated-neutrophils, total-tnf, total-danger). While 
removing inert features did not appear to improve performance, pruning to only 3 features did 
(fig.3.10). We expected to achieve a perfect classification because there was complete separation 
between the two peaks and by 200 ticks we had achieved 0% error rate using 1NN with total-tnf, 
total-danger, and activated-neutrophils. 
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Figure 3.10. Classification accuracy of 200 simulations using a 1-Nearest Neighbor 
approach, trained on 100 simulations. 
The features included in each classifier were as follows: Red – 13Features – all; Blue – 8 Features – total-
damage, activated-macrophages1, activated-mcrophages2, activated-neutrophils, total-tnf, total-tgf, total-
il1, total-danger; Black – 3 Features – activated-neutrophils, total-tnf, total-danger. 
 
3.3.3 Verifying Earliest Decision Point: Re-simulations 
To determine whether 1NN truly identified the decision point in the model, we used the power of 
simulation. For ten simulations (five resulting in ulcers and five resolving), we recorded all 
simulation variables every 25 ticks until t=200. Then, starting from each set of saved simulation 
variables, we initiated 20 simulations and carried them out for 500 additional ticks. In these 
simulations we recorded the same features as above. This yielded 100 simulations from each 
starting tick from variables in resolving simulations and another 100 simulations starting from 
each point in ulcerating simulations. The ulceration status of each of these new simulations was 
noted, and histograms were plotted for each starting tick (see Figs. 3.11 and 3.12). Contrary to 
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the results from 1NN, the simulations seem to be determined before t=125. In all but one source 
simulation, all re-simulations were correctly decided by t=100.  
 
 
Figure 3.11. Histograms of Re-simulation Outcomes: Resolved.  
Results of simulations starting from individual resolving simulations (upper panel) or all resolving 
simulaiton lumped together (lower panel). X-axis represents outcome: 0 = resolved, 1 = ulcerated. 
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Figure 3.12. Histograms of Re-simulation Outcomes: Ulcerated.  
Results of simulations starting from individual resolving simulations (upper panel) or all resolving 
simulaiton lumped together (lower panel). X-axis represents outcome: 0 = resolved, 1 = ulcerated. 
 
 64 
3.3.4 Refining Source and Simulating Interventions 
The above result, combined with the 1NN classification, suggests a course of action for 
preventing ulceration: prevent elaboration of TNF-α before and beyond t=100. It does not, 
however, point to the reason that some simulations achieve this outcome and others do not. In a 
future round of experiments, in order to infer what dynamics are critical to this tipping point, we 
would examine spatial time courses of mediators, cells, tissue health, and oxygen for ticks 50-
150. This time, the outcome measure will be total TNF concentration. We could use information 
from the rules to inform the search. For example, distressed cells produce danger signals (which 
will activate neutrophils to produce TNF-a) except when there is a high enough local 
concentration of TGF-β1. 
3.3.5 Global Sensitivity Analysis 
The goal of a global sensitivity analysis is to understand how changing model parameter values 
affect the outcomes produced in simulations. An important part of this analysis is the question of 
how two or more parameters interact to produce compound results that would not be seen when 
changing one parameter at a time. This is the benefit to using a sampling scheme like orthogonal 
arrays: it allows you to maximize the number of interactions observed while minimizing the 
number of simulations necessary. However, this model has too many parameters to simulate a 
full analysis, even in an orthogonal array. Therefore, a model reduction would be necessary and 
unfortunately most methods of reduction rely on primary effects to choose important parameters. 
Therefore, before embarking on such a reduction, we sought to explore the amount of 
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interactions in the model by performing a sensitivity analysis aimed at observing the relative 
effects of each source of damage.  
We previously identified three sources of damage: lack of oxygen, presence of TNF-α, 
and presence of ROS. These are the three broach mechanistic categories of damage, and for each 
there exists a single parameter that controls the magnitude of its effect in a simulation. These 
“big knobs” were used as the basis of a sensitivity analysis to explore how each mechanism 
contributed to damage and ulceration outcomes. The first level of analysis employed two levels: 
zero-effect and default (Fig 3.13). The zero-effect level of each parameter was defined as the 
value at which that source of damage no longer contributed to a simulation. 
 
 
Figure 3.13. Qualitative SA: Big Knob Sources of Damage. 
Here, we explore the relative effects of three sources of damage: ischemic injury, pro-
inflammatory mediators, and free radicals. O2-epithelial controls the degree to which tissue cells 
respond to local oxygen concentration. Similarly, tnf-epithlial governs their response to tnf. 
Injury-threshold is the concentration of ROS required to damage a tissue cell, which occurs in a 
stepwise manner. The three parameters are set to either their default values or their zero-effect 
value (0 for o2-epithelia and tnf-epithelial, 10 for injury-threshold).  
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Figure 3.14. Qualitative SA: Smaller Parameter Ranges. 
In this analysis, the same three parameters were varied in smaller ranges (default values ± 20%). 
The qualitative results are not very different, but it is evident that increasing sensitivity to oxygen 
leads toqualitatively more irregularly shaped ulcers. 
 
 
 
 
 
Figure 3.15. Examining Bimodality Among Big Knob Parameters. 
X-axes are the values of each parameter and y axis is the number of simulations that incurred the smaller 
amount of damage (reached the second outcome) per ten simulations. 
 
 
In earlier analyses, we examined instances of bimodality wherein simulations with the 
same parameters produced two levels of damage outcomes. With default parameters, we noted 
less damage in approximately 10% of simulations. Here, we examine the marginal effects of 
each big knob parameter on this bimodality. Interestingly, sensitivity to oxygen stands out as the 
best correlated parameter. With these results in mind, a reduced version of the model would 
make sure to include parameters that might have influences on both inflammation and oxygen. 
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3.4 DISCUSSION 
ABMs are a class of models that are simple to construct and therefore accessible to people who 
would normally fall outside of the computational modeling community. This is an advantage of 
this class of model because it allows models to be built from a diverse set of perspectives. 
However, ABMs, like all computational models, require careful consideration of parameters 
when one is trying to model events that track in real time and space. Even with experience and 
awareness of these issues, it is easy for modelers to make mistakes. Sensitivity and uncertainty 
analysis can reveal any mistakes of this nature by showing aberrant behaviors that may not have 
been apparent at a local level. Adding quantitative analysis to what has mostly been a qualitative 
domain heretofore increases the utility of ABMs by increasing their reliability and their 
predictive power. 
A major contribution of this work is the addition of statistical methods and machine 
learning approaches to aid in analyzing ABMs, which is an area that has received little attention. 
We employ these tools with the goal of inferring which mechanisms are most important when 
deciding clinical outcomes. We aimed to apply relatively basic techniques from statistics and 
machine learning to extract salient features from the model in an agnostic and meaningful way. 
We characterized dynamics in the model that appear to be input-independent yet very relevant to 
outcomes. Coupling this analysis with the parameter sensitivity analysis, both that of the 
previous chapter and the process outlined herein, we have developed a relatively thorough 
quantitative characterization of the model, which we could leverage to generate new clinically-
relevant hypotheses. For example, the aleatory uncertainty analysis revealed early pro-
inflammatory mediators and DAMPs as the factors critical determining resolving or ulcerative 
outcomes. However, a second iteration of this analysis should be performed to determine what 
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conditions are necessary to foster the appropriate environment for either stifling or inciting more 
pro-inflammatory activity. Once this is determined, a whole suite of in silico- and clinically-
testable hypotheses will emerge. As another example, global sensitivity analysis suggested that 
decreased damage is associated with reduced sensitivity to oxygen, and reducing sensitivity to 
reactive oxygen species might slow or reduce ulceration. This leads to the hypotheses that 
treatment with antioxidants might be helpful in preventing ulceration, while oxygen should 
decrease cellular damage. While oxygen and antioxidants may not be new ideas for wound 
healing therapies, what is new is the information about how they contribute to pressure ulcer 
formation in different ways. Furthermore, as mentioned above, hyperbaric oxygen therapy has 
not shown promising results in pressure ulcer treatment, but these results indicate that wound 
oxygenation should still be explored as a therapeutic avenue. These hypotheses carry great 
potential for innovation because they are relatable to the overall system, testable in an in silico 
framework where variables such as population variability can be accounted for, and most 
importantly hold exciting potential for applications to patient-specific treatment strategies.  
The quantitative analysis of the PUABM could, of course, extend further. A full 
characterization of global epistemic uncertainty could extend our insights from this model. 
However, it also may not. The PUABM is built at a resolution such that insights can only go so 
deep. To truly understand the dynamics between inflammatory mediators and the cells and 
binding partners in their environment, the time step of the model should be shorter than 1 hour of 
clock time. The biggest advantage of this model is its tissue-realistic output. Another approach to 
formal analysis of this model might be to treat the spatial output as high-dimensional images and 
use feature sets and learning techniques from image analysis to mine for useful diagnostic 
information. 
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4.0  CENTRAL ROLE FOR MCP-1/CCL-2 IN INJURY-INDUCED INFLAMMATION 
REVEALED BY IN VITRO, IN SILICO, AND CLINICAL STUDIES  
This chapter comes from a manuscript that is currently under review at the journal Critical Care 
Medicine. (Ziraldo, C.*; Vodovotz, Y.*; Namas, R.A.; Mi, Q.; Barclay, D.; Almahmoud, K.; 
Jefferson, B.S.; Billiar, T.R.; Zamora, R. Central role for MCP-1/CCL2 in injury-induced 
inflammation revealed by in vitro, in silico, and clinical studies. Submitted) In this work, MCP-1 
was identified as a primary driver of the inflammatory response in primary hepatocytes and then 
shown to correlate with outcomes in human trauma patients. MCP-1 levels predict levels of other 
important inflammatory cytokines, such as IL-6 and correlates with survival rates. My role in this 
work was to design, carry out, and interpret clustering analyses of time-dependent measurements 
of inflammatory mediators, seeking for patterns of dynamic behavior in hepatocyte lysates and 
supernatants. 
4.1 ABSTRACT 
The translation of in vitro findings to clinical outcomes is often elusive. 
Trauma/hemorrhagic shock (T/HS) results in hepatic hypoxia that drives inflammation. We 
hypothesized that in silico methods would help bridge in vitro hepatocyte data and clinical T/HS, 
in which the liver is a primary site of inflammation. Primary C57BL/6 mouse hepatocytes were 
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cultured under hypoxia (1% O2) or normoxia (21% O2) for 1-72 h, and both the cell supernatants 
and protein lysates were assayed for 18 inflammatory mediators. Statistical analyses, hierarchical 
and k-means clustering, Principal Component Analysis, and Dynamic Network Analysis 
suggested MCP-1/CCL2 and IL-1α as central coordinators of hepatocyte-mediated 
inflammation. Hepatocytes from MCP-1-null mice had altered dynamic inflammatory networks. 
Circulating MCP-1 levels segregated human T/HS survivors from non-survivors. Furthermore, 
T/HS survivors with elevated early levels of plasma MCP-1 post-injury had longer total lengths 
of stay, longer intensive care unit lengths of stay, and prolonged requirement for mechanical 
ventilation vs. those with low plasma MCP-1. This study identifies MCP-1 as a main driver of 
the response of hepatocytes in vitro and as a biomarker for clinical outcomes in T/HS, and 
suggests an experimental and computational framework for discovery of novel clinical 
biomarkers in inflammatory diseases.  
4.2 INTRODUCTION 
To inform mechanistic models, we seek a better understanding of the complex signals that drive 
the acute inflammatory response. The following study measured time-dependent levels of 
inflammatory mediators in cells that were stressed by hypoxia or normoxic cell culture over a 
period of 72 hours. From these data, we hoped to discern patterns of interacting cytokines that 
might be key regulators of the overall response. 
Trauma/hemorrhagic shock (T/HS) results in hepatic hypoxia, resulting in a dynamic, 
complex inflammatory response both in the liver and systemically. To define this hepatic 
inflammatory response, primary C57BL/6 mouse hepatocytes were cultured under hypoxia (1% 
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O2) or normoxia (21% O2) for 1-72 h, and both the cell supernatants and protein lysates were 
assayed for 18 inflammatory mediators. Statistical analyses, hierarchical and k-means clustering, 
Principal Component Analysis (PCA), and Dynamic Network Analysis were utilized to define 
the most connected, and thereby possibly controlling, inflammatory mediators as a function of 
time and O2 level. These analyses suggested MCP-1/CCL2 and IL-1α as central coordinators of 
hepatocyte-mediated inflammation. Hepatocytes from MCP-1-null mice exhibited an altered 
inflammatory response to cell stress. Circulating MCP-1/CCL2 levels naturally segregated T/HS 
patients, and patients with elevated early levels of MCP-1/CCL2 post-injury had longer total 
lengths of stay, longer intensive care unit lengths of stay, and prolonged requirement for 
mechanical ventilation. This study identifies MCP-1/CCL2 as a main driver of the response of 
hepatocytes in vitro and as a biomarker for organ damage in clinical settings of T/HS, and 
suggests an experimental and computational framework for discovery of novel clinical 
biomarkers in inflammatory diseases. 
4.3 MATERIALS AND METHODS 
4.3.1 Materials 
Williams Medium E, penicillin, streptomycin, L-glutamine, and HEPES were purchased from 
Invitrogen (Carlsbad, CA). Insulin (Humulin®) was purchased from Eli Lilly (Indianapolis, IN), 
and calf serum was obtained from HyClone Laboratories (Logan, UT). Tissue culture dishes 
were from Corning Glass Works (Corning, NY). Unless indicated otherwise, all other chemicals 
and proteins were purchased from Sigma-Aldrich (St. Louis, MO). 
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4.3.2 Mouse Hepatocyte Isolation and Culture 
All procedures involving animals were approved by the Animal Care and Use Committee of the 
University of Pittsburgh. Primary hepatocytes were harvested from wild-type C57BL/6 mice 
(Charles River Laboratories, Wilmington, MA) or MCP-1/CCL2-null (MCP-1−/−) mice (The 
Jackson Laboratory, Bar Harbor, ME) (52) as previously described (62). Highly purified 
hepatocytes (>98% purity and >95% viability by trypan blue exclusion) were suspended in 
Williams’ E medium supplemented with 10% heat-inactivated calf serum, 15 mM HEPES (pH 
7.4), 16 units insulin, 2 mM L-glutamine, cell culture dishes (3x106 cells/6 cm dish or 5x106 
cells/10 cm dish) and cultured overnight at 37°C under normoxic conditions (5% CO2). The old 
medium was then removed and cells were further incubated with fresh media containing 5% 
heat-inactivated calf serum. Hypoxic conditions were obtained by placing the cells into a 
modular incubator chamber (Billups-Rothenburg, Del Mar, CA) flushed with a hypoxic gas 
mixture containing 1% O2, 5% CO2 and 94% N2. Hepatocytes incubated under normoxic 
conditions (21% O2) served as controls. 
 
4.3.3 Protein Isolation and Sample Preparation  
At the end of each experiment, supernatants were collected and stored at -20°C until further 
analysis. The cell monolayers were then washed twice with ice-cold PBS and resuspended in ice-
cold lysis buffer (Cell Lysis Buffer 10X from Cell Signaling Technology, Danvers, MA) 
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containing 2 mM Tris-HCl buffer (pH 7.5), 15 mM NaCl, 0.1 mM EDTA and EGTA, 0.1% 
Triton X-100, 250 µM sodium pyrophosphate, 100 µM β-glycerolphosphate, 100 µM Na3VO4, 
and the protease inhibitors leupeptin (0.1 µg/ml) and phenylmethylsulfonyl fluoride (PMSF, 
1mM). After 5 min incubation on ice, the cells were scraped off the dish and transferred to 
microcentrifuge tubes. The cells were sonicated two times for 10-15 sec. with 1 min on ice 
between each sonication. Cell debris was then removed by centrifugation at 10,000 rpm for 10 
min and the supernatant was used as cell lysate and stored at -20°C when necessary. An aliquot 
was used to determine protein concentration using the BCA Protein Assay Kit from Pierce 
(Rockford, IL) with bovine serum albumin as standard.  
 
4.3.4 Western Blot Analysis 
Protein samples (50 µg) were separated on 15% SDS-polyacrylamide gels and the gels were 
electroblotted onto PVDF nitrocellulose membranes. Immunodetection of MCP-1/CCL2 protein 
was done using a mouse specific rabbit polyclonal anti-MCP-1 antibody (Cell Signaling, 
Danvers, MA) at 1:1000 dilution, and the immunoreactive bands were visualized after incubation 
with the SuperSignal West Dura Extended Duration Substrate mouse kit (Thermo Scientific, 
Rockford, IL). Instructions for the kit were provided by the supplier. For normalization, the 
membranes were stripped and re-probed with an anti-β-actin antibody from Abcam (Cambridge, 
MA).  
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4.3.5 Measurement of Inflammatory Mediators 
Mouse inflammatory mediators were detected in both cell lysates and supernatants using using 
the MilliplexTM Mouse Cytokine/Chemokine Panel I beadset (Millipore, Billerica, MA) and the 
Luminex™ 100 IS system (Luminex, Austin, TX) as per manufacturer’s specifications. The 
antibody bead kit included: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), 
Interferon-γ (IFN-γ), Interleukin (IL)-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, 
Interferon-γ-inducible Protein 10 (IP-10/CXCL10), Keratinocyte-derived Cytokine 
(KC/CXCL1), Monocyte Chemoattractant Protein-1 (MCP-1/CCL2), Monokine induced by 
Interferon-γ (MIG/CXCL9), Macrophage Inflammatory Protein-1α (MIP-1α/CCL3), Tumor 
Necrosis Factor-α (TNF-α), and Vascular Endothelial Growth Factor (VEGF). 
 
4.3.6 Cell Viability Assay 
Cell viability was assessed by measuring the release of the cytoplasmic enzyme Lactate 
dehydrogenase (LDH) from damaged cells into the supernatant using a colorimetric assay 
Cytotoxicity Detection Kit (LDH assay; Roche Applied Science, Indianapolis, IN). 
 
4.3.7 Statistical Analysis and Data-Driven Modeling 
In an attempt to discern the main drivers of the cellular response and time-dependent changes in 
inflammatory mediators across experimental procedures, we carried out One-way and Two-way 
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ANOVA, hierarchical clustering over both raw data and fold changes, and k-means clustering 
after data was transformed into principal component space. In addition, Dynamic Network 
Analysis (DyNA) was utilized in order to define the principal (most connected and thereby 
possibly controlling) nodes as a function of both time and O2 concentration. Before these 
analyses could be performed and in order to account for experimental variability in cell number, 
cell viability and protein concentration between individual experiments, the final mediator 
concentrations adjusted for protein content (CF) were obtained from the Luminex analysis for 
each individual inflammatory mediator measurement (C) and its respective lysate protein 
concentration (as determined by BCA, see above) using the following formulas: 
 
For cell supernantants: CF = C (pg/ml) x VSN (ml)  BCA (µg protein/µl) x VL (µl)  x 1000 
 
For cell lysates:  CF = C (pg/ml)  BCA (µg protein/ml)   x 1000 
 
The final inflammatory mediator concentrations (CF) are thus expressed in pg/mg total 
protein, where the supernatant volume (VSN) and lysate buffer volume (VL) values used were as 
follows: 
 
Petri Dish Medium Volume (VSN) Lysis Buffer (VL) 
60 mm (3x106 cells) 3 ml 200 µl 
100 mm (5x106 cells) 5 ml 400 µl 
 
Experimental data are presented as mean ± SEM. Data analysis was performed by One-
way or Two-way Analysis of Variance (ANOVA) followed by the Holm-Sidak post-hoc test, and 
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significance of differences in clinical outcomes was determined by Mann-Whitney U test using 
SigmaPlot (Systat Software, San Jose, CA) as indicated. 
 
Before any dynamic analysis, the final inflammatory mediator concentrations (CF) were 
first normalized for each inflammatory mediator, so that all inflammatory mediator levels were 
converted into the same scale (from 0 to 1). All measurements of a given inflammatory mediator 
from a single animal were normalized as a group, by dividing each value by the Euclidean norm 
of the group. In this way, any artifactual effects on variance due to the different ranges of 
concentration observed for different inflammatory mediators were eliminated. 
 
4.3.8 Hierarchical Clustering 
We employed hierarchical clustering to discern and compare dynamic patterns of inflammatory 
mediators in order to identify those inflammatory mediators that show similar behavior in 
production or secretion. This method creates groups (or clusters) of data points by comparing 
individuals according to a prescribed distance metric. The two most similar are clustered together 
and considered a single data point in further rounds. This process continues until all data have 
been joined into a single cluster. It is the order, or hierarchy, of additions to the cluster that 
determines the result. To capture dynamic patterns for each inflammatory mediator, we 
calculated the fold change values by dividing the difference between the later (x2) and earlier (x1) 
inflammatory mediator values by the earlier value: (x2-x1)/x1, where x1 = 0, we replaced 0 with a 
very small number (10-5) to avoid division by zero. Mean fold changes across all animals gave a 
single fold change time course for each inflammatory mediator, which made up the columns of 
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the dendrogram. We employed several MatLab® functions to carry out this analysis: linkage, 
with average link and Pearson correlation distance was used to calculate the distances between 
all pairs of points, and cluster was used to build a hierarchical dendrogram resulting in 2-4 
clusters to compare these dynamic patterns in both fold change and raw data (final inflammatory 
mediator concentrations adjusted for protein content vs. time, unaveraged, all animals included). 
 
4.3.9 Principal Component Analysis and k-means Clustering 
We employed Principal Component Analysis (PCA) to identify the subsets of mediators (in the 
form of orthogonal normalized linear combinations of the original mediator variables, called 
principal components) that are most strongly correlated with a given experimental procedure 
(e.g. normoxia or hypoxia), and that thereby might be considered principal drivers of each 
response. PCA is a statistical method that is widely used in data processing and dimension 
reduction. PCA achieves dimensionality reduction by finding new axes, called principal 
components that identify the linear combinations of signaling axes (in our study mediators). The 
principal components are defined by weighting signals with high covariance and de-emphasizing 
variance of signals that show little covariance with other signals. In this way PCA condenses 
measurements to highlight the global patterns in the data set as reflected by just two or three 
dimensions that capture the maximal covariance between all of the signals. In principal 
component space, the axes represent principal components, and each mediator is plotted as an 
ordered –tuple of its coefficients in each component. A mediator’s covariance may align well 
with the first PC, lending it a high x value in PC space, but not contribute as much to the second 
PC, yielding a smaller y-value in PC space. Mediators with similar patterns of covariance should 
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project in similar directions in PC space. Normalized inflammatory mediator data (each 
measurement taken to be a single point in 18-dimensional inflammatory mediator space) were 
transformed into principal component space using the MatLab® function, princomp. We then 
examined projections of inflammatory mediators into principal component space by using the 
score coefficients for the first 2, 3, or 4 principal components. We employed k-means clustering 
using the MatLab® function, kmeans, using as a distance metric the cosine of the angle between 
a point and the origin. We computed clusters starting with k= 2, 3, or 4 random centroids. At 
each level of k, we repeated the clustering 10 times, resetting new centroids each time and taking 
the lowest mean distance between points and their nearest centroids as the best result. 
 
4.3.10 Meta-Clustering 
To compare the outcomes of the hierarchical and k-means clustering methods (see above), we 
calculated an Adjusted Rand Index (ARI) (44) to quantify to what degree any two clustering 
results were in agreement. This index has been used in gene expression analysis to assess the 
viability of various clustering schemes, including k-means clustering in PCA space, by 
comparing the clustering outcomes to a ground truth classification (97; 107; 108), but to our 
knowledge it has not been used with protein-level data previously. Since our goal was to 
compare the results of k-means clustering in PCA space vs. hierarchical clustering of fold 
changes vs. hierarchical clustering of raw data, we reasoned that we could use the ARI to assess 
the degree of similarity between each pair of clustering results. To do this, the first step was to 
select a single result from each method. For example, how many clusters should be considered, 
and, for PCA, how many principal components should be included? The ARI was first calculated 
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pairwise between clustering results including 2, 3, or 4 principal components. Our strategy was 
to choose the result that captured the most information with the fewest principal components. We 
then used ARI to compare hierarchical clustering results with k= 2, 3, and 4 to k-means 
clustering results with k= 2, 3 and 4 in a pairwise manner. The maximum Rand Index dictated 
the k of the hierarchical and k-means clustering results that were moved forward into further 
analysis. We compared PCA k-means clustering to each of fold change hierarchical clustering 
and raw data hierarchical clustering individually. The k was chosen for k-means clustering that 
maximized both ARI values. 
To distill the most important information from three independent clustering results over 
18 mediators for each of 4 experimental conditions, we filtered the results by discarding 
inflammatory mediators that showed inconsistent segregation patterns across the three analyses. 
The basis of comparison across different experiments was a consensus clustering containing only 
the mediators for whose coordination patterns we had confidence, as shown in detail in Fig. 4.4. 
The consensus clusters combine information from hierarchical clustering: which mediators have 
similar dynamic trajectories—and from PCA: which mediators have the strongest covariance 
with other mediators, and are therefore characteristic of the cells’ response. Mediators that are 
consistently grouped together across all analyses should have strong, coordinated responses to 
cell stress. Briefly, a block of data was constructed with one mediator in each row and its 
corresponding cluster label for each of the three results in the columns using Microsoft Excel®. 
Sorting this block of data by each of the cluster label columns successively allowed us to 
compare the memberships of clusters across the three results and to identify corresponding 
clusters between results. These were clusters that contained a common set of mediators across all 
three results. We used the following heuristic to determine consensus: once a cluster from one 
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result was associated with clusters from the other results, (e.g. Cluster A from Raw Data was 
associated with Cluster 2 from Fold Change and Cluster IV from PCA clustering) it could not be 
associated with any other clusters. For example Cluster 1 could not associate with both Cluster A 
and Cluster B. Mediators that did not segregate into corresponding clusters across all results 
were deemed inconsistent and omitted from the consensus clustering result. This consensus 
outcome became the basis of comparison among experimental conditions (see Figure 4.4). 
 
4.3.11 Dynamic Network Analysis (DyNA) 
The goal of this analysis was to gain insights into dynamic changes in network connectivity of 
the cellular response to normoxia and hypoxia over time, and this analysis was carried out 
essentially as published previously (63). To do so, inflammatory mediator networks were created 
over time periods between consecutive measurements (1-3 h, 3-6 h, 6-24 h, 24-48 h, and 48-72 
h) using Matlab® and Inkscape® software (http://inkscape.org/). In order to be included in the 
DyNA, a given mediator had to be statistically significantly different from its baseline value (no 
treatment [time = 1 h]; P< 0.05 by Student’s t-test). Connections in the network were created if 
the correlation coefficient between two nodes (inflammatory mediators) was greater or equal to a 
threshold of 0.7 (based on a total of 12 samples with 10 degrees of freedom, P<0.05). 
 
4.3.12 Human Trauma Patient Selection and Analysis 
All human sampling was done following approval by the University of Pittsburgh Institutional 
Review Board and informed consent was obtained from each patient or next of kin as per 
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Institutional Review Board regulations. From a cohort of 493 blunt trauma patients admitted to 
Presbyterian University Hospital (part of the University of Pittsburgh Medical Center), we 
selected 62 patients (all survivors) separated into two groups matched on age, gender, and Injury 
Severity Score (ISS): 31 normotensive patients (19 males and 12 females; systolic blood pressure 
>90 mmHg, mean age: 44.4 ± 2.2 years, range: 24-75 years, mean ISS: 23.5 ± 1.3, range: 10-38), 
matched with 31 hypotensive patients (19 males and 12 females; systolic blood pressure <90 
mmHg, duration of hypotension post-injury: 8 ± 1 h, range: 2-21 h, mean age: 45.1 ± 3.4 years, 
range: 20-89 years, mean ISS: 23.5 ± 2.2, range: 4-54). One to four blood plasma samples per 
patient were collected within the first 24 h post-injury, followed by additional sampling at 48, 72, 
and 96 h. All blood samples were stored at -80°C until analysis. MCP-1/CCL2 and IL-6 were 
measured using the Luminex™ 100 IS system and the Human 25-plex® Luminex™ beadset 
(BioSource, now Invitrogen) or the MilliplexTM MAP kit (Millipore, Billerica, MA).  
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4.4 RESULTS 
4.4.1 MCP-1/CCL2 is a central component of the dynamic, multi-dimensional 
response of hepatocytes to cell stress 
To assess the response of hepatocytes to hypoxia, we subjected primary wild-type mouse 
hepatocytes to 1% O2 for various periods of time (1, 3, 6, 24, 48, and 72 h), followed by 
Luminex™ analysis of 18 mouse cytokines and chemokines in both the supernatant and whole-
cell lysate. Control hepatocytes were cultured under normoxic (21% O2) conditions. To 
determine which mediators changed significantly across time, and under which experimental 
conditions, one-way ANOVA was performed over of the time courses for each inflammatory 
mediator in both lysates and supernatants (Table 4.1). The results showed significant differences 
in various inflammatory mediators, depending on experimental treatment, time point, and 
cellular localization: while in the normoxia control group only three mediators showed 
significant changes (MCP-1/CCL2, KC/CXCL1, and IP-10/CXCL10 in lysates, and MCP-
1/CCL2, KC/CXCL1, and MIG/CXCL9 in supernatants), in the hypoxia group the number of 
mediators showing statistically significant changes increased (MCP-1/CCL2, MIG/CXCL9, IL-
1α, IL-1β, IL-10, and IL-13 in lysates; MCP-1/CCL2, IP-10/CXCL10, IL-1α, and VEGF in 
supernatants). Notably, MCP-1/CCL2 was the only mediator that exhibited significant changes 
in all four conditions examined (Table 4.1). The experimental values for this mediator are shown 
in Fig. 4.1. These results suggested that MCP-1/CCL2 is a central player in the differential 
production of key cytokines and chemokines by hepatocytes in response to cellular stress.  
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Table 4.1: One-way ANOVA p-values (wild-type) 
Significance levels (P<0.05) for production and release of inflammatory mediators from wild-type 
mouse hepatocytes cultured under normoxic or hypoxic conditions (1-72 h) as determined by one-
way ANOVA. *For hypoxia time courses, the analysis was performed using as baseline the 
respective concentration values for normoxia at 1 h. 
 Normoxia Hypoxia* 
 Lysate Supernatant Lysate Supernatant 
GM-CSF 0.721 1 0.753 0.086 
IFN-γ 0.105 1 0.452 1 
IL-1α 0.591 1 0.023 0.007 
IL-1β 0.559 0.664 0.026 0.886 
IL-2 0.126 0.929 0.24 0.919 
IL-4 0.901 0.942 0.935 0.656 
IL-5 1 1 0.123 0.101 
IL-6 0.091 0.914 0.223 0.059 
IL-10 0.346 0.947 0.035 0.832 
IL-13 0.601 1 0.002 0.65 
IL-17 0.98 0.921 0.958 0.999 
IP-10 0.045 0.513 0.135 0.046 
KC 0.002 <0.001 0.374 0.283 
MCP-1 0.001 <0.001 0.003 <0.001 
MIG 0.15 0.002 0.016 0.177 
MIP-1α 0.636 0.416 0.081 0.543 
TNF-α 0.987 0.685 0.056 0.999 
VEGF 0.271 <0.001 0.073 <0.001 
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Figure 4.1 Inflammatory mediator production by normoxic and hypoxic primary mouse 
hepatocytes.  
Freshly isolated hepatocytes from C57BL/6 (wild-type) mice were cultured under normoxic 
(control, 21% O2, open symbols) or hypoxic (1% O2, closed symbols) conditions for 1, 3, 6, 24, 48 
and 72 h as described in Materials and Methods. At the end of the experiments, samples from both 
lysates and supernatants were assayed for 18 mouse inflammatory mediators using the Luminex 
xMAP technology and the measurements were normalized for protein content as indicated. (A) 
MCP-1/CCL2 expression and release in primary mouse hepatocytes. Results are the mean ± SEM 
(n=4-8 independent experiments) and were analyzed by Two-Way ANOVA followed by the 
Holm-Sidak post-hoc test (*P<0.001, normoxia vs. hypoxia within a specific time point). The 
insets show the levels of MCP-1/CCL2 in hypoxia samples. 
 
4.4.2 Hierarchical Clustering and Principal Component Analysis reveal key 
differences in inflammatory mediator production/release in the hepatocyte response to 
cell stress 
From the analysis above, we showed that, in addition to MCP-1/CCL2, other inflammatory 
mediators also change significantly over the time course of our studies. In order to address the 
question of which groups of mediators have similar dynamic trajectories, we performed 
hierarchical clustering on fold changes for each mediator at each pair of consecutive time points. 
We calculated the fold change values for all mediators over each time interval, in order to assess 
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how quickly the concentration of a given inflammatory mediator changed relative to its earlier 
value. Taken together, each inflammatory mediator’s set of fold change values over time made 
up its dynamic pattern of expression and release. To identify those inflammatory mediators that 
showed similar production or secretion behavior, these patterns were then compared and grouped 
using hierarchical clustering, with inflammatory mediators in the resulting dendrogram ordered 
according to their membership in the clusters that emerged (Fig. 4.2; see Materials and Methods 
for methodological details). The fold change values for each inflammatory mediator are 
represented in heat maps, ranging from large negative (green) to large positive values (red). No 
changes (zero values) are represented in black (Fig. 4.2). We repeated the same clustering 
process with raw inflammatory mediator measurements as well, which was also used for meta-
clustering analysis (see below). Analysis of the heat maps showed different grouping patterns in 
the experimental groups (normoxia vs. hypoxia) both in lysates and supernatants (Fig. 4.2). 
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Figure 4.2: Hierarchical clustering over fold changes in wild-type hepatocytes (normoxia vs. 
hypoxia).  
Fold change values for each inflammatory mediator are represented in heat maps, ranging from 
large negative (green) to large positive values (red). Zero fold changes are represented in black 
(see Materials and Methods and Results for full description and analysis). 
 
 
We also sought to determine the subset of mediators that evolve dynamically in a manner 
that is most characteristic of the response to normoxia or hypoxia, respectively. Inflammatory 
mediators that have similar patterns of covariance have similar loadings onto principal 
components, and so would be expected to project in a similar direction in principal component 
space. We therefore used the angle of an inflammatory mediator’s projection into PCA space as 
the basis of a distance metric in k-means clustering, as described in Materials and Methods. The 
resulting clusters contain mediators that have similar patterns of covariance with the remaining 
mediators. The inflammatory mediator groupings according to k-means clustering are shown in 
Fig. 4.3 for lysates (Panel A for normoxia and Panel B for hypoxia) and supernatants (Panel C 
for normoxia and Panel D for hypoxia). Despite an overlap in common mediators, k-means 
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clustering served to differentiate normoxia from hypoxia and lysates from supernatants in 
primary hepatocytes, where more than 60% of the total variance could be explained by the 
combination of only three principal components in all experimental conditions (Fig. 4.3A-D). 
We found that MCP-1/CCL2 and KC/CXCL1 were generally grouped together and were the 
predominant mediators along the first principal component (Fig. 4.3A-D). In normoxia lysates, 
MCP-1/CCL2 and KC/CXCL1 have the strongest covariance with each other and other 
mediators suggesting that these mediators may have the strongest signal in response to stress 
(Fig. 4.3A). Furthermore, in hypoxia lysates MCP-1/CCL2, KC/CXCL1, and MIG/CXCL9 are 
strongly correlated to each other as well as the overall covariance of all inflammatory mediators 
measured in hypoxia lysates, but the strongest response signal was carried by IL-2 and IL-4 (Fig. 
4.3B). In normoxia supernatants, two sets of inflammatory mediators see to explain most of the 
covariance, but are anti-correlated with each other: KC/CXCL1, MCP-1/CCL2, VEGF, and 
MIG/CXCL9 all oppose signals from IL-1β, IL-10 and IP-10 (Fig. 4.3C). In hypoxia 
supernatants, the covariance of the response was dominated by IL-5, IL-6, and MIP-1α/CCL3 
(Fig. 4.3D). Overall, in lysates the strongest stress response seems to be from MCP-1/CCL2 and 
KC/CXCL1 together. In supernatants, these chemokines contribute, but to the secondary and 
tertiary, not primary responses. 
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Figure 4.3: PCA and k-means Clustering. 
Relevant inflammatory mediator groupings in the hepatocyte response to normoxia or hypoxia as 
determined by consensus of clustering methods. Freshly isolated hepatocytes from wild-type mice 
were cultured under normoxic (control, 21% O2) or hypoxic (1% O2) conditions for 1, 3, 6, 24, 48 
and 72 h as described in Materials and Methods. At the end of the experiments, samples from both 
lysates (L) and supernatants (SN) were assayed for 18 mouse inflammatory mediators using the 
Luminex xMAP technology, the measurements were normalized for protein content and over each 
inflammatory mediator and each sample and k-means clustering was performed over dynamic 
inflammatory mediator measurements from 4 experimental conditions (N vs. H, and L vs. SN) 
using MatLab® software as described in the Materials and Methods. The tridimensional grouping 
of significant inflammatory mediators according to k-means clustering is represented as follows: 
(A) normoxia lysate, (B) hypoxia lysate, (C) normoxia supernatant, and (D) hypoxia supernatant. 
(The percentage of total variance corresponding to each analysis is shown on the top of the 
graphs).  
 
 
We next sought to compare the results of the three aforementioned, independent 
clustering experiments. If the cluster memberships were similar, then those mediators that did 
not segregate consistently across different clusterings of a process could be treated as noise. In 
contrast, those inflammatory mediators that consistently segregated together were considered to 
 89 
be the mediators that truly exhibited similar or correlated dynamic trajectories, and thus could be 
important drivers or indicators of the response of hepatocytes to either normoxia or hypoxia. To 
compare the outcomes of the hierarchical and k-means clustering methods, we performed a meta-
clustering analysis (Fig. 4.4, see Materials and Methods), which resulted in a “consensus 
clustering” showing the inflammatory mediators that exhibited the same segregation pattern 
across all analysis methods. We found that MCP-1/CCL2 and KC/CXCL1 segregated together 
across all experimental conditions in every clustering experiment (Fig. 4.5). 
 
 
Figure 4.4: Meta-clustering process: from three independent clustering results to a 
consensus clustering. Example: wild-type Hypoxia Lysates. 
Each method is colored one hue (blue = hierarchical clustering of raw data, orange = hierarchical 
clustering on fold changes, green = k-means clustering in PCA space) and clusters within each 
method are demarcated by shades and tones of each hue. Each column was then sorted 
alphabetically by mediator names and the clustering results were combined into a single matrix. 
The rows of this matrix were sorted by cluster labels, sequentially. This sorting allowed visual 
identification of clusters that were associated across methods. In this case the rows were first 
sorted according to PCA clusters, then by fold change cluster labels, and finally by raw data 
cluster labels. From here, a consensus can be determined by following a heuristic: identify 
associated clusters, identify and remove inconsistent mediators. For example, it is plain to see that 
a majority of mediators from Cluster A are also found in Cluster 2 and Cluster I. Therefore, these 
three clusters are considered to be the same. Any mediators associated with Cluster A, but not 
with both Cluster 2 and Cluster I were then marked as inconsistent and discarded from the 
analysis. One special case is when two clusters from one method fuse together to associate with 
clusters from other methods. In this case, Clusters C and D both associate with Cluster 4 and 
Cluster III. As long as neither C nor D associate with any other clusters, this is permitted. 
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Figure 4.5: Comparison of the outcomes of the hierarchical and k-means clustering methods 
using meta-clustering.  
The shading of the boxes indicates the grouping of inflammatory mediators that exhibited the 
same segregation pattern across all methods. For each experimental condition, only the mediators 
appearing in the consensus are shown in this figure. Furthermore, to compare two experimental 
conditions, we show only the mediators present in both consensuses (with ten mediators remaining 
in each comparison, very few mediators had to be omitted in the comparison step). 
 
 
4.4.3 A predominant role for MCP-1/CCL2, KC/CXCL1, and IL-1α in the 
hepatocyte response to stress inferred from Dynamic Network Analysis 
The preceding meta-clustering analysis allowed us to define groups of inflammatory mediators 
that had similar patterns as they changed in time (see above). We then used the Luminex™ time 
courses of mediators to determine how these associations changed across time. In order to 
identify the dynamic connections among inflammatory mediators, to determine which mediators 
appear to be “hubs” (or most connected to other mediators), and to delineate the changes in this 
architecture over time, we performed Dynamic Network Analysis (DyNA) as published 
previously (63) and described in the Materials and Methods. These analyses were performed for 
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each of the following time intervals: 1-3 h, 3-6 h, 6-24 h, 24-48 h, and 48-72 h. Summaries of 
DyNAs showing principal inflammatory mediator “hubs” of the response to normoxia and 
hypoxia are shown in Figs. 4.6 and 4.7, respectively. The total number of connections resulting 
from these analyses is shown in Fig. 4.8. Based on DyNA, MCP-1/CCL2 and KC/CXCL1 were 
the most connected mediators across all time points in normoxia supernatants, and at 24-72 h in 
normoxia lysates (Fig. 4.6). In hypoxia, the most connected inflammatory mediators were IL-1α 
and VEGF in supernatants and IL-1α and MIP-1α/CCL3 in lysates (Fig. 4.7). Overall, the most 
connected inflammatory mediators were MCP-1/CCL2 and IL-1α, with MCP-1/CCL2 being the 
only highly-connected node present in all experimental conditions examined (Fig. 4.8). 
 
 
 
Figure 4.6. Dynamic Network Analysis (DyNA) of inflammatory mediators produced by 
normoxic mouse hepatocytes.  
Primary hepatocytes from wild-type mice were cultured under normoxic conditions (1-72 h) 
followed by measurement of inflammatory mediators in both lysates and supernatants and lysates 
as described in Materials and Methods. After data normalization, Dynamic Network Analysis 
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during each of the following five time frames: 1-3 h, 3-6 h, 6-24 h, 24-48 h, and 48-72 h was 
performed for both normoxia lysates and normoxia supernatants as indicated. The most connected 
mediators—those that were correlated with the greatest number of other mediators in a time step—
are shown here. Each mediator’s node size is proportional to the number of connections it has in a 
given time interval. When correlated to other represented mediators, they are illutrated as 
touching. Other highly connected mediators that are not connected to mediators illustrated here are 
show not touching. MCP-1 is hgihlighted in black. A dotted circle indicates a high negative 
correlation between two touching mediators. 
 
 
 
Figure 4.7. Dynamic Network Analysis (DyNA) of inflammatory mediators produced by 
hypoxic mouse hepatocytes.  
Primary hepatocytes from wild-type mice were cultured under hypoxic conditions (1-72 h) 
followed by measurement of inflammatory mediators in both lysates and supernatants and lysates 
as described in Materials and Methods. After data normalization, Dynamic Network Analysis 
during each of the following five time frames: 1-3 h, 3-6 h, 6-24 h, 24-48 h, and 48-72 h was 
performed for both hypoxia lysates and hypoxia supernatants as indicated. The most connected 
mediators—those that were correlated with the greatest number of other mediators in a time step—
are shown here. Each mediator’s node size is proportional to the number of connections it has in a 
given time interval. When correlated to other represented mediators, they are illutrated as 
touching. Other highly connected mediators that are not connected to mediators illustrated here are 
show not touching. MCP-1 is hgihlighted in black. A dotted circle indicates a high negative 
correlation between two touching mediators. 
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Figure 4.8: Total Connections in DyNA analyses across experimental conditions.  
The stacked bars represent the total number of connections for each inflammatory mediator over 
all time intervals. Each color stands for one experimental condition. IL-1a, MCP-1 and VEGF had 
the highest number of connections overall. Notably, MCP-1 was the only mediator that was 
connected in all four experimental conditions. 
 
 
4.4.4 Inflammatory dynamics and networks are disrupted in hepatocytes from 
MCP-1−/− mice 
Our in vitro studies and computational analyses led us to hypothesize a central role for MCP-
1/CCL2 in the response of mouse hepatocytes to cell stress. To test this hypothesis, we 
performed analogous experiments using primary hepatocytes from MCP-1−/− mice. As in our 
studies in wild-type mouse hepatocytes, freshly isolated hepatocytes from MCP-1−/− mice were 
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subjected to hypoxia (1% O2) for various periods of time (1-72 h), followed by Luminex™ 
analysis of 18 mouse cytokines/chemokines in both the lysates and the supernatants and using 
normoxic cells as control. 
 
We first sought to verify that MCP-1/CCL-2 was absent in MCP-1−/− mice. As shown in 
Fig. 4.9, normoxic hepatocytes from MCP-1−/− mice did not express MCP-1/CCL2 protein by 
Western blot, while a weaker band of approximately 30 kDa was detected in the lysates from 
hypoxic cells. In contrast, MCP-1/CCL2 protein expression was significantly higher in cell 
lysates of both normoxic and hypoxic hepatocytes from wild-type mice at 48 and 72 h (Fig. 4.9). 
This analysis suggested the low, but detectable, presence of a protein with MCP-1/CCL2-like 
characteristics in the nominally MCP-1−/− mice. 
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Figure 4.9. MCP-1/CCL2 is a central component of the dynamic, multi-dimensional response 
of hepatocytes to cell stress.  
Primary hepatocytes from wild-type and MCP-1−/− mice were cultured under normoxic (N) or 
hypoxic (H) conditions for 1-72 h, followed by Luminex™ analysis of 18 inflammatory mediators 
in both the supernatant (SN) and whole-cell lysate (L). The measurements were normalized and 
hierarchical and k-means clustering was performed as described in Materials and Methods. A 
representative Western blot showing MCP-1/CCL2 protein expression in cell lysates from 
normoxic (N) and hypoxic (H) MCP-1−/− and wild-type mouse hepatocytes (48 and 72 h) and 
densitometric analysis as described in Materials and Methods.  
 
 
 
Following normalization of the Luminex data for protein content, we performed one-
way ANOVA for each inflammatory mediator in both lysates and supernatants of MCP-1−/− 
hepatocytes (Table 4.2). Based on this analysis, we observed differences in the mediators that 
changed over time depending on both the experimental treatment and the cellular localization as 
compared to wild-type hepatocytes (see Table 4.1). As in the wild-type cells, only three 
mediators in the normoxia group showed significant changes (MIG/CXCL9, KC/CXCL1, and 
IL-6 in lysates; KC/CXCL1, IL-1β, and VEGF in supernatants), while more inflammatory 
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mediators showed statistically significant changes in the hypoxia group (MIP-1α/CCL3, IL-1α, 
IL-1β, IL-2, IL-6, IL-10, IL-13, IFN-γ, and TNF-α in lysates; KC/CXCL1, IL-1α, and VEGF in 
supernatants). 
 
Table 4.2: One-way ANOVA p-values (MCP-1-/-) 
Significance levels (P<0.05) for production and release of inflammatory mediators from MCP-1−/− 
mouse hepatocytes cultured under normoxic or hypoxic conditions (1-72 h) as determined by one-
way ANOVA. *For hypoxia time courses, the analysis was performed using as baseline the 
respective concentration values for normoxia at 1 h. 
  Normoxia Hypoxia* 
  Lysate  Supernatant Lysate Supernatant 
GM-CSF 0.918 0.535 0.239 0.423 
IFN-γ 0.897 0.371 <0.001 0.53 
IL-1α 0.869 0.249 0.002 0.034 
IL-1β 0.748 0.031 0.008 0.369 
IL-2 0.978 0.332 0.006 0.282 
IL-4 0.982 0.669 0.978 0.054 
IL-5 0.757 1 0.379 1 
IL-6 <0.001 0.475 <0.001 0.403 
IL-10 0.439 0.696 <0.001 0.57 
IL-13 0.191 0.888 <0.001 0.978 
IL-17 0.992 0.995 0.96 0.945 
IP-10 0.783 0.572 0.925 0.518 
KC <0.001 <0.001 0.234 0.009 
MCP-1 0.823 0.535 0.573 0.782 
MIG 0.003 0.761 0.609 0.068 
MIP-1α 0.363 0.078 0.009 0.653 
TNF-α 0.833 1 0.002 1 
VEGF 0.599 <0.001 0.242 0.019 
 
 
As we did for the wild-type hepatocytes, we next used Luminex™ mediator 
measurements from MCP-1−/− cells as the basis for meta-clustering (of hierarchical clustering 
over raw data, hierarchical clustering over fold changes, and k-means clustering in PCA space) 
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and Dynamic Network Analysis. As before, the fold change values for each inflammatory 
mediator are represented in heat maps, ranging from large negative (green) to large positive 
values (red). The absence of changes from baseline is represented in black (Fig. 4.10). As was 
the case for the wild-type hepatocytes, hierarchical clustering over fold changes resulted in 
different grouping patterns between the two experimental groups (normoxia vs. hypoxia) both in 
lysates and supernatants and also when comparing the MCP-1−/− (Fig. 4.10) vs. wild-type mouse 
hepatocytes (see Fig. 4.2 for comparison). 
 
Figure 4.10. Hierarchical clustering over fold changes in MCP-1−/− hepatocytes (normoxia vs. 
hypoxia).  
Fold change values for each inflammatory mediator ranging from large negative (green) to large 
positive values (red) are shown. No fold changes (zero values) are represented in black.  
 
 
 
We next carried out k-means clustering over inflammatory mediator measurements 
transformed into PCA space. In normoxia lysates as well as hypoxia lysates (Fig. 4.11) and 
supernatants, MCP-1−/− hepatocytes) most of the variance could be explained by a linear 
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combination of only two principal components (in contrast to wild-type cells; see Figs. 4.3A-D 
for comparison). Despite using cells from MCP-1-/- mice, MCP-1/CCL2 still appeared to 
contribute to the overall variance of the response to cellular stress. However, this chemokine 
plays a less prominent role, with its coefficients causing it to be found closer to the origin when 
projected into principal component space. In normoxia lysates, all inflammatory mediators 
seemed to associate along the strongest directions of covariance, led by GM-CSF. KC/CXCL1 
was the exception, characterizing the secondary response (Fig. 4.11). In hypoxia lysates, the 
primary response was dominated by IFN-γ, but included most other mediators to varying 
degrees. A secondary response was characterized by a cluster containing KC/CXCL1, VEGF, 
IL-4, and IP-10 (Fig. 4.11). In normoxia supernatants, a cluster containing KC/CXCL1 and 
VEGF was associated with the primary response, while in hypoxia supernatants, the primary 
response was characterized by two opposing clusters: KC/CXCL1, VEGF, and others oppose IL-
6 and IL-2 along the strongest direction of covariance (Fig. 4.11D). Overall, in MCP-1-/- 
hepatocyte lysates, all inflammatory mediators generally co-varied together. In cells exposed to 
either hypoxia or normoxia, a secondary signal that was uncorrelated to the first was carried by a 
set of mediators including KC/CXCL1, but not MCP-1/CCL2. In MCP-1-/- hepatocyte 
supernatants, we observed an anti-correlated response consisting of KC/CXCL1 and VEGF. 
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Figure 4.11. The grouping of significant inflammatory mediators according to k-means 
clustering.  
Panels are arranged as follows: (A) normoxia lysate, (B) hypoxia lysate, (C) normoxia 
supernatant, and (D) hypoxia supernatant. (The percentage of total variance corresponding to each 
analysis is shown on the top of the graphs).  
 
 
As in the analysis of the responses of wild-type hepatocytes to cells stress, and in order to 
synthesize the outcomes of the hierarchical and k-means clustering methods in the MCP-1−/− 
hepatocytes, we next performed meta-clustering. In contrast to the same analysis in wild-type 
cells (see Fig. 2.5 for comparison), IL-1β and MCP-1/CCL2 clustered together across all 4 
experimental conditions (Fig. 4.12). 
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Figure 4.12. Comparison of the outcomes of the hierarchical and k-means clustering 
methods using meta-clustering.  
The shading of the boxes indicates the grouping of the inflammatory mediators that exhibited the 
same segregation pattern across all methods. 
 
 
4.4.5 Dynamic Network Analysis of inflammatory mediators produced by 
normoxic and hypoxic mouse hepatocytes isolated from MCP-1−/− mice 
We next carried out DyNA of lysates and supernatants from normoxic and hypoxic MCP-1−/− 
hepatocytes. A summary of the this analysis, showing the principal inflammatory mediator 
“hubs” during the five time frames (1-3 h, 3-6 h, 6-24 h, 24-48 h, and 48-72 h), is shown in Figs. 
4.13 (normoxia) and 4.14 (hypoxia). The total number of connections resulting from this analysis 
is shown in Fig. 4.15. This analysis suggested a significant decrease in the number of 
connections (Figs. 4.13-14) in both lysates and supernatants of normoxic cells and in hypoxia 
supernatants as compared to wild-type hepatocytes (Figs. 4.6-7). While in normoxia supernatants 
KC/CXCL1 was the most significantly changed mediator (with nearly zero connections across 
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all time points; Fig. 4.13), in hypoxia supernatants this chemokine was a central node without 
connections only at 24-72 h (Fig. 4.14). In normoxia lysates, IL-6 was the most significantly 
changed mediator, but had no connections to other mediators (Fig. 4.13). However, this cytokine 
was the most connected mediator (along with IFN-γ) in hypoxia lysates at all-time intervals after 
6 h (Fig. 4.14). DyNA suggested a clear lessening in the total number of dynamic connections 
among inflammatory mediators in MCP-1−/− cells (Fig. 4.15) as compared to wild-type 
hepatocytes (Fig. 4.8). The most connected inflammatory mediator in MCP-1−/− hepatocytes was 
IL-6, but only in hypoxia lysates (Fig. 4.8). 
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Figure 4.13. Dynamic Network Analysis (DyNA) of inflammatory mediators produced by 
normoxic mouse hepatocytes isolated from MCP-1−/− mice.  
Primary hepatocytes from isolated from MCP-1−/− mice were cultured under normoxic conditions 
(1-72 h) followed by measurement of inflammatory mediators in both lysates and supernatants as 
described in Materials and Methods. After data normalization, DyNA was performed for both 
normoxic lysates and normoxic supernatants during each of the following five time frames: 1-3 h, 
3-6 h, 6-24 h, 24-48 h, and 48-72 h as indicated. The most connected mediators—those that were 
correlated with the greatest number of other mediators in a time step—are shown here. Each 
mediator’s node size is proportional to the number of connections it has in a given time interval. 
When correlated to other represented mediators, they are illutrated as touching. Other highly 
connected mediators that are not connected to mediators illustrated here are show not touching.  
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Figure 4.14. Dynamic Network Analysis (DyNA) of inflammatory mediators produced by 
hypoxic mouse hepatocytes isolated from MCP-1−/− mice.  
Primary hepatocytes from isolated from MCP-1−/− mice were cultured under hypoxic conditions 
(1-72 h) followed by measurement of inflammatory mediators in both lysates and supernatants as 
described in Materials and Methods. After data normalization, DyNA was performed for both 
hypoxic lysates and hypoxic supernatants during each of the following five time frames: 1-3 h, 3-6 
h, 6-24 h, 24-48 h, and 48-72 h as indicated. The most connected mediators—those that were 
correlated with the greatest number of other mediators in a time step—are shown here. Each 
mediator’s node size is proportional to the number of connections it has in a given time interval. 
When correlated to other represented mediators, they are illutrated as touching. Other highly 
connected mediators that are not connected to mediators illustrated here are show not touching. 
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Figure 4.15. Total Connections in DyNA analyses across experimental conditions in MCP-1-/- 
cells.  
The stacked bars represent the total number of connections for each inflammatory mediator over 
all time intervals. Each color stands for one experimental condition. Notably, no mediator had 
connections in more than one experiemental condition in MCP-1-/- cells. 
 
 
4.4.6 Differential expression and release of IL-6 in mouse hepatocytes: wild-type vs. 
MCP-1−/− 
Because one-way ANOVA and DyNA revealed that the most significant changes in 
inflammatory mediator production and release were observed for MCP-1/CCL2 and IL-6, we 
decided to examine the time courses for IL-6 in more detail. Primary hepatocytes from wild-type 
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and MCP-1−/− mice were cultured under normoxic and hypoxic conditions for 1-72 h followed by 
Luminex™ analysis in both the whole-cell lysates and supernatants as described in the Materials 
and Methods. IL-6 levels were significantly lower in both normoxia lysates (Fig. 4.16A) and 
supernatants (Fig. 4.16B) of MCP-1−/− hepatocytes as compared to wild-type controls. In 
hypoxia lysates, IL-6 showed no significant changes in protein expression (though the values 
tended to decrease after the 24 h) (Fig. 4.16C). In contrast, IL-6 increased over time in 
supernatants from wild-type hepatocytes, but not in MCP-1−/− cells (Fig. 4.16D). These results 
suggest that the differential expression and release of IL-6 in mouse hepatocytes depends, at least 
in part, on MCP-1/CCL2. 
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Figure 4.16. Time-dependent expression and release of IL-6 in mouse hepatocytes.  
Primary hepatocytes from wild-type (open symbols) and MCP-1−/− (closed symbols) mice were 
cultured under normoxic (Panels A and B) and hypoxic (Panels C and D) conditions for 1, 3, 6, 
24, 48 and 72 h followed by measurement of IL-6 in both lysates and supernatants using the 
Luminex™ xMAP technology as described in Materials and Methods. Results are the mean ± 
SEM (n=4-8 independent experiments, analyzed by Two-way ANOVA, P<0.05 (wild-type vs. 
MCP-1−/−) for all conditions except hypoxia lysates, Panel C). 
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4.4.7 In situ hepatocyte expression of MCP-1 and IL-6 is attenuated in MCP-1−/− 
cells  
The differential expression of MCP-1 and IL-6 in both wild-type and MCP-1−/− cells was 
confirmed using confocal immunofluorescence (Fig. 4.17A). Quantitative analysis of the images 
(Fig. 4.17B) revealed that MCP-1 is indeed elevated in wild-type hepatocytes as compared to 
MCP-1−/− cells, with much higher levels in normoxia vs. hypoxia, confirming the results obtained 
by Luminex measurements (see Fig. 4.1). Similarly, cellular IL-6 levels were lower in the MCP-
1−/− cells as compared to wild-type hepatocytes, especially under hypoxic conditions (Fig. 
4.17B). 
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Figure 4.17. Differential expression of MCP-1 and IL-6 in wild-type and MCP-1−/− 
hepatocytes.  
Primary hepatocytes isolated from wild-type and MCP-1−/− mice (n=3 each) were cultured under 
normoxic and hypoxic conditions for 48 h in three independent experiments. The cells were then 
fixed and processed for confocal immunofluorescence imaging as described in the Materials and 
Methods. (A) Fluorescent labeling: Phalloidin (white), MCP-1 (red), IL-6 (green), Hoechst (blue). 
(B) Quantification of immunostained cells (fluorescence intensity from 600-700 hepatocytes from 
3 independent fields, n=3 coverslips/experiment). Results are the mean ± SEM (*P<0.001 wild-
type vs. MCP-1−/−, analyzed by t-test). 
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4.4.8 Elevated plasma MCP-1/CCL2 levels as biomarker for morbidity in human 
trauma/hemorrhage 
Our in vitro findings suggested that MCP-1/CCL2 is central to the production and release of 
hepatocyte inflammatory mediators in response to cellular stress (key among them being IL-6). 
Since the liver is a central organ in the in vivo response to T/HS, and since IL-6 has been 
identified consistently as a marker of negative outcomes in T/HS, we next evaluated the potential 
of plasma MCP-1/CCL2 levels to serve as a biomarker for morbidity in blunt trauma patients. 
Indeed, an analysis of a cohort of 30 trauma patients revealed that patients could be segregated 
between survivors and non-survivors based on plasma MCP-1 levels within the first 24 h (Fig. 
4.18).  
 
Figure 4.18: MCP-1 levels in plasma samples from trauma patients  
Survivors vs. non-survivors, n=15 each taken within the first 24 h after trauma as described in the 
Materials and Methods. Results represent the mean ± SEM (The dotted line represents the mean 
value, *P=0.001, survivors vs. non-survivors analyzed by t-test). 
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We next studied a cohort of 31 hypotensive patients matched with 31 normotensive 
patients as described in the Materials and Methods. We first sought to verify our in vitro/in 
silico-derived hypothesis that MCP-1/CCL2 levels are correlated with IL-6 levels. Plasma MCP-
1/CCL2 and IL-6 levels in both patient cohorts are shown in Fig. 4.19. Plotting IL-6 vs. MCP-
1/CCL2 plasma concentrations for the trauma patient cohort as a whole (n=62) suggested that 
circulating IL-6 levels in these patients could be segregated into two groups based on circulating 
MCP-1/CCL2 levels: low MCP-1 (<1000 pg/ml, Panels A-B) and high MCP-1 (>1500 pg/ml, 
Panels A-B). Furthermore, analysis of the data showed a positive correlation between MCP-
1/CCL2 and IL-6 in both normotensive (correlation coefficient= 0.59, Panel A) and hypotensive 
(correlation coefficient= 0.41, Panel B) blunt trauma patients. 
 
Figure 4.19: Elevated plasma MCP-1/CCL2 levels are associated with morbidity in human 
trauma/hemorrhage.  
Plot of IL-6 vs. MCP-1/CCL2 levels in blood samples from normotensive (A) and hypotensive (B) 
trauma patients (n=31 each) taken within the first 24 h after trauma, followed by sampling at 48, 
72 and 96 h as described in Materials and Methods.  
 
 
We then performed a different grouping irrespective of blood pressure status and based 
solely on MCP-1/CCL-2 concentrations (<1000 pg/ml and >1500 pg/ml, respectively). This 
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grouping reduced the study cohort to 46 T/HS patients. We found that T/HS patients with lower 
circulating MCP-1/CCL-2 levels (Fig. 4.20, left; 400.54 ± 15.75 pg/ml; range: 12.13 - 991.67 
pg/ml [n=38;]) have lower circulating IL-6 levels (106.14 ± 8.07 pg/ml; range: 3.42 - 682.11 
pg/ml [n=38]) as compared to patients with higher circulating MCP-1/CCL-2 (Fig. 4.20, right; 
4098.71 ± 772.85 pg/ml; range: 1486.46 - 26112.26 pg/ml [n=8]) who exhibited higher, though 
more variable circulating IL-6 levels (1457.67 ± 391.23 pg/ml; range: 26.12 - 10582.37 pg/ml 
[n=8]).  
 
Figure 4.20. Grouping of T/HS patients based on circulating MCP-1/CCL2 levels.  
Left hand panel shows MCP-1 values <1000 pg/ml (n=38 patients), right hand panel shows values 
>1500 pg/ml (n=8 patients).  
 
 
We next sought to determine if these two cohorts of patients, segregated solely on the 
basis of circulating MCP-1/CCL-2 levels, exhibited any differences in outcomes. Patients with 
higher circulating MCP-1 levels had worse outcomes, as indicated by a longer total length of stay 
(LOS), longer intensive care unit (ICU) LOS, and greater requirement for mechanical ventilation 
(Fig. 4.21). Interestingly, statistical analysis using two-way ANOVA showed no significant 
differences between MCP-1/CCL2 levels in the initial cohort of normotensive vs. hypotensive 
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patients (data not shown), and analysis of the clinical outcomes of the patients segregated based 
on their normotensive/hypotensive status revealed no differences between normotensive and 
hypotensive patients (data not shown).  
 
Figure 4.21. Overall demographics of T/HS patients segregated according to plasma MCP-
1/CCL2 levels.  
Low MCP-1(<1000 pg/ml; [n=38 patients]) vs. high MCP-1 (>1500 pg/ml; [n=8 patients]). 
Results represent the mean ± SEM. (*P<0.05, analyzed by Mann-Whitney U test, MCP-1<1000 
pg/ml vs. MCP-1>1500 pg/ml).  
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4.5 DISCUSSION 
Liver ischemia and subsequent reperfusion, which can occur in T/HS and resuscitation, lead to 
inflammatory liver injury as well as to the systemic elaboration of inflammatory mediators and 
subsequent multiple organ dysfunction (37; 72; 79). Liver hypoxia is a primary feature of HS in 
experimental models (46; 60). Hypoxic stress, however, is but one of a variety of stresses (e.g. 
endoplasmic reticulum stress and autophagy) encountered by hepatocytes in settings such as 
T/HS (33) and I/R (35). We therefore reasoned that the analysis of synthesis and secretion of 
inflammatory mediators by stressed hepatocytes would help in our understanding of the 
pathophysiology of T/HS and other conditions characterized, at least in part, by hepatic stress. 
Our key finding is that a combined in vitro/in silico analysis of the dynamics of synthesis 
and secretion of inflammatory mediators points to the chemokine MCP-1/CCL2 as a central 
coordinator of the inflammatory response of stressed hepatocytes, a finding that allowed us to 
segregate blunt trauma patients based on circulating levels of MCP-1/CCL2. Importantly, this 
segregation of patients would have proven ineffective if performed based on the patients’ 
normotensive/hypotensive status post-injury. 
Chemokines (also known as chemotactic cytokines) are small cytokine-like, heparin-
binding molecules which play a major role in orchestrating immune and stem cell infiltration into 
the liver in response to acute and chronic injuries (37; 78). Hepatic chemokines are released not 
only during inflammatory injury (infection, drug intoxication), but these mediators play a key 
role in the activation and proliferation of liver-resident cells (including hepatocytes, stellate cells 
and endothelial cells) and thus help drive hepatic regeneration after partial hepatectomy (25; 78). 
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In our studies, multiple chemokines were synthesized by stressed hepatocytes. Though 
chemokines are often thought to be highly redundant in their actions, MCP-1/CCL2 was the only 
mediator that exhibited significant changes in both normoxia and hypoxia, and in both cell 
lysates (denoting cellular expression) and supernatants (denoting secretion by cells). Our 
findings of perturbed dynamic inflammatory networks in MCP-1−/− mice supports the hypothesis 
that this chemokine plays a central driving role in the hepatocyte response to stress. The presence 
of a weaker, but noticeable, MCP-1/CCL2 protein band in the lysates from hypoxic MCP-1−/− 
cells raises the possibility that the actual effects of MCP-1/CCL2 might be even more 
pronounced. 
MCP-1 or chemokine (C-C motif) ligand 2 (CCL2) is one of the best-known CC 
chemokines. It was first identified as a monocyte-specific chemoattractant, and was later shown 
to attract memory T lymphocytes and NK cells. Binding to its seven transmembrane G-protein-
coupled receptor CCR2 (CC chemokine receptor 2) results in signaling events that lead to the 
recruitment of monocytes to inflammation in a variety of in vivo experimental models of 
infection and injury (24; 42). In addition to recruiting monocytes, MCP-1/CCL2 can also activate 
macrophages and endothelial cells and has been implicated in the attraction of neutrophils and 
the generation of neutrophil-dependent tissue damage (42). Lu et al. showed that despite normal 
numbers of circulating leukocytes and resident macrophages, MCP-1−/− mice were specifically 
unable to recruit monocytes 72 h after intraperitoneal thioglycollate administration, indicating 
that MCP-1 is essential for monocyte recruitment and the expression of cytokines related to T 
helper responses in vivo (52). 
Hepatic MCP-1/CCL2 can be upregulated in vivo by I/R (103) as well as by bacterial 
endotoxin (16), and in isolated mouse hepatocytes by hypoxia (49) and the present study). The 
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expression of MCP-1/CCL2 in normoxic primary cultured hepatocytes has been thought to be 
due to the stress of the cell isolation procedure (96), and we likewise found elevated MCP-
1/CCL2 in normoxic hepatocytes. The effects of MCP-1/CCL2 in the liver range from protective 
(e.g. in experimental acetaminophen-induced injury) to detrimental (e.g. during experimental I/R 
injury) (49). 
In addition to MCP-1/CCL2, our studies suggest that IL-1α, IL-6, KC/CXCL1, and 
MIG/CXCL9 exhibit the most significant dynamic changes in stressed hepatocytes. Our results 
suggest that MCP-1/CCL2 regulates the production of these other inflammatory mediators. This 
hypothesis is supported by prior studies, in which the expression of hepatic pro-inflammatory 
cytokines (including IL-6 and KC/CXCL1) was induced in alcohol-fed wild-type, but inhibited 
in MCP-1−/− animals (57). In support of this central role for KC/CXCL1, Frink et al showed that 
neutralization of this chemokine ameliorated liver damage after T/HS in mice. These authors also 
showed that MCP-1/CCL2 causes organ damage via upregulation of KC/CXCL1, supporting our 
findings of a network of hepatic inflammation that involves these two chemokines. However, the 
exact source of KC/CXCL1 remained unknown (38), and our present study suggests that 
hepatocytes are a key source of this chemokine.  
Interleukin-6 is a biomarker of poor outcome in trauma (54; 106). It is therefore notable 
that IL-6 was highly correlated with MCP-1/CCL2 in T/HS patients, and that the production of 
IL-6 by hypoxic hepatocytes was essentially abolished in the absence of endogenous MCP-
1/CCL2. Interestingly, a recent study suggests the presence of a positive feedback loop involving 
IL-6 and MCP-1/CCL2 in a setting of vascular inflammation (89). 
The use of applied mathematical models and algorithms constitute a novel tool for 
interpreting complex biological data. In 2005, a pioneering study in this field constructed a 
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systems model comprising a large number of intracellular signaling events directly linked to 
outputs associated with apoptosis to study how molecular information is processed as a network 
(45). Prior studies have also utilized advanced computational analyses to discern key features of 
the inflammatory biology of hepatocytes. For example, Alexopoulos et al studied 26,000 protein 
state measurements from isolated primary human hepatocytes and HepG2 liver cancer cells 
exposed to growth factors or inflammatory mediators, yielding interaction graphs using 
multilinear regression (2). The authors suggested major differences between primary and 
transformed hepatocytes with respect to toll-like receptor-4 signaling and NF-κB-dependent 
secretion of chemokines and cytokines, and suggested, as we do here, that combined in vitro/in 
silico analyses can yield novel insights into hepatocyte biology (2). More recently, Boolean logic 
models of immediate-early signaling in liver cells were created by training a literature-based 
prior knowledge network against biochemical data obtained from primary human hepatocytes as 
well as four hepatocellular carcinoma cell lines exposed to combinations of cytokines and small-
molecule kinase inhibitors (77). Our present study extends this paradigm to define key nodes in 
the stress-induced inflammatory networks induced in hepatocytes, as well as suggesting higher-
order, clinically-applicable insights. Indeed, this study points to various similarities between 
hepatocytes in vitro and T/HS in vivo. For example, as in the present study, we found in a prior 
study of experimental T/HS in mice that together with MIG/CXCL9, IL-6 was highly elevated 
but disconnected from other inflammatory mediators (63). Our present study raises the 
possibility that MCP-1/CCL2 is the stimulus for post-HS MIG/CXCL9 and IL-6. 
In the present study, we developed a novel algorithm for consensus clustering of multiple 
data-driven analyses of dynamic responses. We hypothesized that those inflammatory mediators 
exhibiting the most coordination across experimental conditions could be important drivers or 
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indicators of that process. The strategy we employed was to extract patterns from dynamic data, 
and to assess the measure of similarity across multiple dynamic patterns. To distill the most 
important information from three independent clustering results over 18 mediators for each of 4 
experimental conditions, we filtered the results by discarding inflammatory mediators that 
showed inconsistent segregation patterns across the three analyses. A consensus clustering 
containing only the mediators whose coordination patterns in which we could be most confident 
was the basis of comparison across experimental conditions. This method identified MCP-
1/CCL2 as the most relevant mediator in our studies. 
This novel approach to data-driven modeling suggested the key aspect of our study, 
namely that trauma patients can be segregated into high- vs. low-producers of MCP-1/CCL2, and 
that circulating levels of MCP-1/CCL2 are better discriminators of outcome post-trauma than 
hypotension in our moderately-injured patients. This was true despite the fact that even a brief 
period of hypotension was suggested to elevate post-trauma morbidity and mortality in injured 
patients (109). Collectively, our results provide a systems view of the hepatocyte inflammatory 
response to cell stress, with implications for ischemia and hemorrhage, and point to hepatocytes 
as a likely cellular source of cytokines/chemokines in the inflammatory response. Furthermore, 
these results highlight the capacity of data-driven analyses for suggesting novel, clinically-
relevant targets. 
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5.0  CONCLUSIONS 
In this dissertation, I have explored the role of computational methods in elucidating biological 
information from complex systems. In each problem, the goal was to bridge from a confounding 
biological problem to a clinical solution using computational tools to shed insights along the 
way. 
In an in vitro model of cellular stress, we identified a small set of interacting mediators 
that were elucidated consistently and with similar patterns. We showed that without one of those 
key mediators, the entire inflammatory milieu elucidated during cell stress was shifted. And most 
importantly, we showed that there was a strong correlation between levels of this mediator and 
inflammatory outcomes in human trauma patients. High levels of MCP-1 were associated with 
high levels of IL-6, a mediator that has been shown to be a hallmark of inflammation. 
Furthermore, high MCP-1 levels correlated with non-survival outcomes in human trauma 
patients. 
An agent-based model of pressure ulcer formation successfully incorporated multiple 
levels of mechanistic information and produced tissue-realistic simulations that were comparable 
to images of pressure ulcers in people with spinal cord injury (SCI). This model was successfully 
used as a hypothesis testing platform to assess the viability of treatment strategies, including 
dosage and timing considerations. The visual output of the model also predicted morphological 
features (e.g. satellite ulcers, irregular shaped ulcer edges) that were observed in patients, but not 
 119 
coded into the model. And, importantly, the inflammatory dynamics in the model exhibited the 
ability to reach two different steady states from the same initial conditions: resolving 
inflammation or unresolving, damaging positive feedback. 
We then used computational tools to further explore the behaviors of the model, in order 
to pinpoint the players involved in the decision point between resolving and damaging 
inflammatory paradigms. Simulations provided an unending supply of training and testing data 
for classifiers that were trained on time series of model components (cells, mediators, cell 
properties, etc.). And finally, taking advantage of the spatial output of the model, local 
information could be gleaned in order to understand the decision process from the point of view 
of a single cell, rather than a whole tissue. The most natural next step with this ABM is to use 
image analysis techniques to bridge between the spatial output of the model and the clinical 
images that are the most reliable source of data for comparison. This model could continue to 
serve as a hypothesis-testing platform or with some increased functionality could be put to use as 
a diagnostic tool. 
All of the experiments described here represent waypoints on a path from data to clinical 
interventions. From data, patterns can be inferred, and from patterns mechanisms. Mechanisms 
can be synthesized with other mechanisms to generate hypotheses. And after validating the 
hypothesis-generating platform, it can be used to test new hypotheses and strategies before 
developing them for clinical (or even animal) trials. Another important part of this arc is the idea 
that these transitions from one medium to the next do not happen in isolation; we are not 
suggesting an automated pipeline. Instead, experts are chauffeuring the insights along, checking 
that the outputs generated make sense in the context, and using domain knowledge and 
experience to interpret them and decide in what form they are passed to the next step. We have 
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illustrated a few parts of this path, but all of them are ongoing, if disjointedly. Computational 
methods are being used to boost the power of experimental results, allowing data from disparate 
sources to be related and new inferences to be made. 
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APPENDIX A 
PUABM PSEUDOCODE 
Key: 
 
AGENTS 
 Agents’ properties 
 DATA LAYERS – In rules, this refers to the local value of a data layer 
 User-defined-parameters 
 functions-defined-inside-PUABM 
 ∝: “is proportional to” 
  
At tick t, do the following: 
- Reset tissue-health = 0    
- Reset total-damage = 0 
- If t mod shear-interval == 0, apply or release shear 
- Data Layers diffuse: TNF, TGF, IL-1B, O2, DAMPs, ROS, STEROID, ANTIDAMPS 
- Data Layers evaporate: TNF, TGF, IL-1B, O2, DAMPs, OXIDASE, ROS, 
ANTIOXIDANT, STEROID, ANTIDAMPS 
- If t mod pressure-interval == 0, apply or release pressure by changing values of 
data layer, PRESSURE 
- In a randomly determined order,  
o EPITHELIAL CELLS make-step: 
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 Border = false 
 Velocity = 0 
 If t > antidamps-onset and [(t – antidamps-onset) mod antidamps-
reapply == 0], set ANTIDAMPS = antidamps-dose  
 If alive, epithelial-function: 
• Set ANTIOXIDANT = antiox-level 
• If O2 < 0.75, increase OXIDASE 0.01 
• If O2 > 0 and OXIDASE > 0, make ROS ∝ O2 and OXIDASE 
• If ANTIOXIDANT > 0 and ROS > 0  
o decrease ROS ∝ ANTIOXIDANT and ROS 
o decrease ANTIOXIDANT ∝ ANTIOXIDANT and ROS 
• If ANTIDAMPS > 0 and DAMPS > 0: with probability damps-
bind 
o Decrease DAMPS ∝ ANTIDAMPS and DAMPS 
o Decrease ANTIDAMPS  ∝ ANTIDAMPS and DAMPS 
• If ROS > 0, increase injury-index ∝ ROS 
• If injury-index > injury-threshold decrease life 90% 
• Decrease life ∝ (shear force)2 
• Decrease life ∝ TNF, IL-1B, 1 - O2 
• Increase life ∝ TGF, O2 
• Set color 
• If life < 0 
o Increase total-damage 1 
o Alive = false 
o Die, exit 
• Life > 100  100 
• If life < 100, increase total-damage ∝ life 
• Increase tissue-health ∝ life 
• Increase DAMPs ∝ exp(-life/100) 
 Else,  
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• If neighbors alive, border = true 
• Increase total-damage 1 
o BLOOD VESSELS make-step: 
 Size scales ∝ (1 - PRESSURE)4 
 If one or fewer neighboring EPITHELIAL CELLS are alive, die 
 Hatch one MACROPHAGE with probability ∝ size 
 Hatch one NEUTROPHIL with probability ∝ size 
 If d > 0.0001, hatch one NEUTROPHIL 
 Increase OXYGEN ∝ size 
 If t > steroid-onset, set STEROID = steroid-dose 
o MACROPHAGES make-step: 
If STEROID > mac-steroid-toxicity  
• if state ==1, decrease activated-macrophages1 by 1 
• if state ==2, decrease activated-macrophages2 by 1 
• die, exit 
Else: 
 Wiggle 45° 
 Jump 
 Sniff TGF with probability 0.5 
 Else, with probability 0.3: 
• Sniff TNF, then 
• Sniff IL-1B 
 Else don’t sniff anything 
 If TNF > tnf-activation-mac  or IL-1B > il1-activation-mac 
• state = 1 with probability = 1 / (1 + il1-activation-mac) 
• increase activated-macrophages1 
• color = red 
• if previous state == 2, decrease activated-macrophages2 by 
1 
 If TGF > tgf-activation-mac  or IL-1B > il1-m2-activation 
• state = 2 with probability = 1/1+(tgf-activation-mac) 
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• increase activated-macrophages2 
• color = green 
• if previous state == 1, decrease activated-macrophages1 by 
1 
 decrease age 1 
 if age < 0 
• if state ==1, decrease activated-macrophages1 by 1 
• if state ==2, decrease activated-macrophages2 by 1 
• die, exit 
o NEUTROPHILS make-step: 
If STEROID > pmn-steroid-toxicity  
• increase ROS 0.001 
• if state ==1, decrease activated-neutrophils 1 
• die, exit 
Else: 
 Wiggle 45° 
 Jump 
 Sniff DAMPs 
 If state == 0 and DAMPs > danger-pmn-activation 
• State = 1 
• Color = black 
• Increase age 3-8 ticks 
 If state == 1, increase TNF ∝ (1+TNF)/(1+TGF) 
 If state == 0 
• If TGF < 0.001  
o survey EPITHELIAL CELLS in a neighborhood of 
radius 1 
o if their mean life < 90, state == 1 
 decrease age 1 
 if age < 0 
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• increase ROS 0.001 
• if state == 1, decrease activated-neutrophils 
• die, exit 
- Query values of: total-TNF, total-TGF, total-danger, total-pressure, total-oxygen, 
blood-flow, total-antioxidant, total-antidamps, total-ROS, total-oxidase, activated-
macrophages1, activated-macrophages2, activated-neutrophils, epithelial-
number 
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